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ABSTRACT
CHARACTERIZATION OF DNA-BINDING PROTEINS AS CLINICALLY
RELEV ANT BIOMARKERS OF BREAST CANCER BEHAVIOR

Traci L. Kruer
November 17,2011

While investigating estrogen response element (ERE) binding properties of ERa
in de-identified human breast cancer extracts, additional proteins were observed that
recognized ERE sequences (ERE-BP). In order to unravel the apparent role of these
proteins, our goal was to compare properties of these novel ERE-BP with those of ERa,
determine their identity and evaluate their clinical relevance in breast cancer behavior.
ERE-BP were present in various tissue types including breast, ovarian, uterine and colon
cancers and normal tissues. These proteins were present in both cytoplasm and nuclei
although higher binding activities were detected in nuclear extracts. ERE-BP did not
supershift with numerous anti-ERa or

ER~

antibodies recognizing different ER epitopes

suggesting that they are not fragments of either ERa or

ER~.

ERE-BP competed with

rhERa for binding to the VitA2-ERE yet overall exhibited significantly different
sequence specificity compared to that of human ERa. The ERE-BP we observed in breast
cancer extracts were not specific for ERE sequences. To further support this conclusion,
various estrogens had no effect on the ERE-binding of these proteins in contrast to
rhERa. Furthermore, ERE-BP activities were not correlated with levels of expression of
IV

in either ERu- or ERE-mediated transcription. An immune-based method was established
for purifying ERE-BP from tissue extracts and proteins were identified by mass
spectrometry. Ku70 (XRCC6) and Ku80 (XRCC5) were determined to be the most likely
candidates for the identity of ERE-BP. Supershift assays confirmed that ERE-BP/ERE
complexes observed by EMSA were specifically recognized by antibodies to the
Ku70/Ku80 heterodimer (Ku). Western blotting with Ku70/Ku80 antibodies confirmed

their presence in breast cancer extracts. Increased Ku DNA-binding activities in cytosols
of breast biopsies correlated with higher grade tumors, positive lymph node status and
decreased patient survival. Also increased Ku DNA-binding activities in cancers from
patients receiving adjuvant chemotherapy correlated with decreased survival, suggesting
Ku DNA-binding activities may be used to predict response to treatment. Collectively,
our results suggest that Ku DNA-binding activities in cytosols prepared from carcinoma
biopsies are useful biomarkers for assessing breast cancer recurrence and response to
therapy.
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CHAPTER I
INTRODUCTION AND PRELIMINARY RESULTS

Breast Cancer Overview

Carcinoma of the breast cancer is the most common cancer affecting women in
the United States with over 200,000 new cases estimated in 2010 and more than 39,000
deaths [1]. It is the second most common cause of cancer death in women, and the main
cause of death in women ages 40 to 59, although the incidence has been decreasing by
1.8% per year from 1999-2007 [1;2]. Current risk estimates suggest that a woman who
lives to the age of90 has a 1 in 8 chance of developing breast cancer [3].

Breast cancer etiology and risk/actors

The most common risk factors for developing breast cancer are age, benign breast
disease, young age of menarche, late age of first live birth, a first-degree relative with
breast cancer and race [1 ;4;5]. Additional risk factors include excessive estrogen
exposure, radiation exposure, environmental toxins, smoking, diet, obesity and exercise
[3 ;5-9]. The effects of these are not fully understood.
Breast cancers may be divided into sporadic and hereditary cases. Only 13% of
women with breast cancer report a family history in a first-degree relative [4].
Approximately 3% of all breast cancers and 25% of those classified as hereditary cancers
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can be attributed to mutations in the genes BRCAI and BRCA2 [3]. Both of these genes
act as tumor suppressors and are involved in DNA repair and cell cycle control [3]. A key
function for BRCAI and BRCA2 is to prevent genomic instability from progressing after
DNA damage occurs [10]. BRCAI and BRCA2 are highly penetrant and have a large
effect on risk but are rare. Approximately 10% of hereditary breast cancers are attributed
to mutations in other known genes [11]. These genes include CHEK2, p53, PTEN and
ATM [3;12;13]. CHEK2 gene encodes a cell cycle checkpoint kinase protein and
functions to repair DNA damage by activating BRCAI [14]. The p53 gene encodes a
well studied transcription factor that is involved in the G I checkpoint of the cell cycle
and mutations in this gene increase the risk of genomic instability in the cell [13].
Furthermore, the PTEN gene encodes a protein tyrosine phosphatase whose inactivation
results in elevated Akt activity and abnormal growth regulation [15-17]. Lastly, the ATM
gene encodes a protein kinase that phosphorylates BRCAI in response to DNA damage
[13]. These genes are moderately penetrant and their combined effects are not fully
understood.
Sporadic breast carcinomas comprise the majority of all breast cancer cases. For
sporadic breast cancer, the major risk factors are related to estrogen exposure [3].
Hormone replacement therapy increases the risk of developing breast cancer [18], and
combined hormonal therapy with estrogen and progestins may further increase breast
cancer risk [19]. The majority of sporadic breast cancers occur in post-menopausal
women and more than 60% of the lesions over-express the estrogen receptor [3 ;20].
Many studies have examined the mechanisms by which estrogens influence
differentiation and proliferation of cells that may result in aberrant signaling through
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estrogen-dependent pathways, thought to be a major mechanism for hormone receptor
positive breast cancers [20-24]. However, additional mechanisms playa role in sporadic
cancers as a significant number of breast carcinomas are ER negative [25;26]. Clearly,
breast cancer is a complex disease determined by environmental and genetic components.

Prognostic and predictive factors of breast cancer

The 5-year survival rates for women with breast cancer vary from 98% for
patients with localized disease at diagnosis to 23% for patients with distant disease at
diagnosis [1]. Several major indicators are used at the time of diagnosis to determine
prognosis of a breast cancer patient and are integrated into the American Joint Committee
on Cancer (AJCC) staging system [27]. These prognostic indicators provide information
on clinical outcome independent of therapy and are related to cancer growth, invasion
and metastatic potential [28]. The major prognostic factors of breast cancer are invasive
carcinoma, distant metastases, axillary lymph node metastases, tumor size, locally
advanced disease and inflammatory carcinoma [3]. The most significant of these factors
in the absence of distant metastases is lymph node status [3;29]. For node negative
patients, the lO-year disease-free survival rate is 70% to 80% [3]. For patients with up to
three positive nodes, the 10-year survival rate drops to 35% to 40% [3]. This rate drops to
10% to 15% for breast cancer patients with more than 10 positive nodes. The second
most important prognostic factor is tumor size [3]. The 5-year survival rate for a woman
with a carcinoma less than 1 cm in diameter is approximately 92.6%; however the 5-year
survival rate for a woman with a carcinoma greater than 5 cm in diameter drops to 62.9%
[30].
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These major prognostic factors are integrated into the AlCC staging system [27]
and are divided into stages O-IV. Stage 0 consists of ductal carcinoma (DCIS) in situ or
lobular carcinoma in situ (LCIS). These have not invaded beyond the basement
membrane and have not yet metastasized [3;27]. The 5-year survival rate of patients with
these carcinomas is 92% [3]. Stage I carcinomas are locally invasive tumors less than 2
cm in diameter without nodal involvement [3;27]. The 5-year survival rate is 87% [3].
Stage II carcinomas are invasive tumors less than 5 cm in diameter with up to three
positive lymph nodes or invasive tumors greater than 5 cm in diameter without nodal
involvement. The 5-year survival rate of patients with these cancers is 75% [3]. Stage III
breast carcinomas consist of invasive tumors less than 5 cm in diameter with at least 4
positive axillary lymph nodes as well as invasive tumors greater than 5 cm in diameter
with positive lymph nodes, invasive tumors with 10 or more positive lymph nodes,
invasive tumors with involvement of the internal mammary lymph nodes, skin, or chest
wall and inflammatory cancer [3]. The 5-year survival rate for these cancers is 46% [3].
Stage IV breast cancers are invasive tumors of any size with the presence of distant
metastases. The 5-year survival rate for patients with these cancers is only 13% [3].
There are also several minor factors that provide useful clinical information
regarding prognosis. These include histologic subtypes (e.g. ductal, tubular, mucinous,
medullary, lobular, papillary and cribiform), tumor grade, lymphovascular invasion,
proliferation rate and DNA content [3; 12; 13]. Tumor grade is a measure of tumor
differentiation that takes into account tubule formation, nuclear pleomorphism and
mitotic counts [31]. The 10-year survival rates are 85%, 60% and 15% for welldifferentiated (grade I), moderately differentiated (grade II) and poorly differentiated
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(grade III) tumors, respectively [3]. Observation of tumor cells within the lymphatics or
capillaries (lymphovascular invasion) is associated with increased lymph node
involvement and poorer prognosis [3]. Proliferation rate can be measured by flow
cytometry (S-phase fraction), thymidine labeling index or immunohistochemical
detection of cellular proteins (e.g., cyclins, Ki-67) [3]. High proliferation rates are
associated with a poorer prognosis [32]. The DNA content of a cell is also correlated with
prognosis while aneuploid tumors are indicative of poor prognosis [3;33;34].
Certain molecular factors in breast carcinoma biopsies are used to predict the
liklihood of a patient responding to a specific treatment. The three most commonly used
predictive factors are the estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) status [3;35]. ER and PR are members of the
nuclear hormone receptor superfamily and function as ligand dependent transcription
factors [36]. It is reported that 60-70% of breast cancers express ER [12;20;35].
Furthermore, patients with tumors that over-express ER and/or PR are most likely to
respond to endocrine therapy [20;24-26;35;37]. Many studies report that 80% of patients
with tumors that are ER+/PR+ respond to endocrine therapy [3]. Approximately forty
percent of patients with tumors that are positive for one of these receptors respond to
endocrine therapy, whereas only 10% ofER-/PR- tumors respond [3;12;25;26].
Originally ER and PR were measured a ligand binding assay (LBA) that was
developed into an FDA-approved assay [23;38-40]. In this assay, ligand

(17~-estradiol

for ER, progestin (R5020) for PR) labeled with either [12sIodine] or eH-tritium] is
incubated with cytosols prepared from tissue biopsies under conditions allowing the
ligand to bind to the receptor. Free steroid is separated by addition of dextran-coated
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charcoal and removed by centrifugation. The amount of receptor-bound labeled steroid
hormone in the supernatant is then measured using a scintillation counter [23;38-40]. The
results are used to create a Scatchard plot [41]. From this plot, the concentration of the
receptor protein in the cytosol is determined and generally expressed as femtomoles of
receptor per mg protein (fmol/mg protein). The cutoff value approved by the FDA for ER
or PR positivity using this assay is 2: 10 fmol/mg protein [35]. Importantly, a Kd value
estimating the affinity of the ligand for the receptor protein is also derived.
Beginning in the 1980's, ER and PR levels were also quantified by enzyme
immunoassay (EIA). This is an antibody based method that also requires the use of
cytosols from fresh tissues [42]. In this assay, cytosols are incubated with a monoclonal
antibody attached to a polystyrene bead. The protein/antibody-bead complex is separated
by centrifugation, resuspended and incubated with a secondary antibody conjugated to
the enzyme horseradish peroxidase. A colorimetric substrate is added and converted to
yield a color change that can be measured by spectrophotometry and the values are
plotted on a standard curve for quantification [42-44]. The cutoff approved by the FDA
for ER and PR positivity using this assay is 2: 15 fmol/mg protein [35]. The advantage of
both LBA and EIA is that the receptors are measured quantitatively [20;45]. The LBA is
the only procedure that determines the affinity of the receptor for its ligand, usually
expressed as the Kd value. However, both assays require fresh-frozen specimens and a
considerable amount of tissue.
Currently, the predominate assay used for clinical measurement of ER and PR
levels is immunohistochemistry (IHC) [35]. IHC is also an antibody based assay and can
be performed on either frozen or formalin-fixed, paraffin-embedded (FFPE) tissue
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sections mounted on glass slides [46;47]. Sections are incubated with monoclonal
antibodies followed by incubation with a secondary antibody conjugated to the enzyme
horseradish peroxidase. A colorimetric substrate is then added which is converted to a
colored product that is detected by microscopy and the amount of ER or PR protein can
be semi-quantified based on the number of positive cells and the intensity of staining.
The advantage of IHC over EIA or LBA is that it can be performed on a variety of
specimens and requires very little tissue. The disadvantage of IHC is assay variability and
lack of standardization [48-50].
The HER2 gene encodes a transmembrane glycoprotein with intrinsic tyrosine
kinase activity [51]. This protein belongs to the epidermal growth factor receptor (EGFR)
family of receptors and is involved in the signal transduction pathways controlling cell
growth and differentiation [52]. Amplification of the HER2 gene has been correlated with
both shorter disease-free and overall survival in breast cancer [53]. Tumors that overexpress HER2 are less likely to respond to certain chemotherapies than tumors with
normal HER2 levels [54]. However, these tumors are more likely to respond to therapies
that target HER2 itself (e.g. trastuzumab) [55]. HER2 may be measured by IHC, PCR or
fluorescence in situ hybridization (FISH) [12;13].

Treatment of breast cancer

Surgical removal of the tumor is the standard initial treatment for primary breast
cancers with no evidence of distant metastases. This therapeutic approach may be breastconserving or involve surgical removal of the entire breast [56]. Surgery may then be
followed with adjuvant radiation therapy, chemotherapy, endocrine therapy (e.g.
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tamoxifen) or targeted therapy (e.g. trastuzumab) depending on the size of the tumor,
lymph node involvement, presence of ER, PR and HER2 and other risk factors for
recurrence.

Endocrine therapy

Due to the estrogen-dependent nature of many breast cancers, endocrine therapies
have been developed to prevent tumors from responding to stimulation by endogenous
estrogens. In the 1950's, ovarian ablation was the standard therapy for women with breast
cancer. This therapy was most effective in women with ER+ and/or PR+ tumors [57]. In
the early 1970's, it was reported that ER+ tumors were more likely to respond to
endocrine ablation than ER- tumors [58]. Several studies reported that approximately
60% of patients with ER+ tumors responded to endocrine therapy, while only 8% of
patients with ER- tumors responded to the same therapy [59;60]. These observations led
to the development of tamoxifen for the treatment of breast cancer [61-64]. Currently,
tamoxifen is the most commonly used endocrine therapy for breast cancers that are ER
and/or PR positive. Fifty to eighty percent of these tumors respond to tamoxifen, while
only 5-10% of ER-/PR-tumors respond [65-68]. Tamoxifen is a selective estrogen
receptor modulator (SERM) and acts as an inhibitor of growth and proliferation of breast
cancer cells by competitive antagonism of ER [69]. Another SERM, raloxifene, is used
for reduction in risk of invasive breast cancer in postmenopausal women [70]. Another
class of endocrine therapy for treatment of breast cancer is composed of aromatase
inhibitors (e.g. anastrozole, letrozole, exemestane). Aromatase inhibitors work by
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inhibiting aromatase, the enzyme which converts androgenic precursors into estrogens
[67;71].

Estrogen Receptor Biology
ER is a member of the nuclear hormone receptor superfamily and acts as a liganddependent transcription factor [72]. Two ER isoforms, ERa and ERP, mediate estrogen
actions in target tissues [73]. The structure of these ER proteins can be divided into six
functional domains. The N-terminal AlB domain contains a transactivation function (AF)
which promotes the transcriptional activation of target genes [74;75]. The C region
contains the DNA-binding domain, which is responsible for ERE recognition and
dimerization [75;76]. ER binds to the ERE through two type II zinc fingers formed by the
coordination of a zinc atom with four cysteine residues [75-78]. The D region joins the
DNA-binding and ligand-binding domains and is referred to as the hinge region [74;75].
This region allows the receptor to bend and alter conformation and also contains a
putative nuclear localization sequence [75;79;80]. The E region contains the ligandbinding domain and is responsible for hormone binding and activation of transcription
[74;75]. The C-terminal F domain modifies the interaction of ER with coregulators and
plays a role in the response to agonist and antagonist ligands [81-83].
The DNA-binding domains of ERa and ERP share 97% homology; however the
ligand-binding domains share only 59% homology [84;85]. Although both isoforms are
expressed in breast tissue, currently the biological and clinical roles of ERP are being
evaluated [84;86]. A clinical application of ERP has not yet been accepted for the

9

management of breast cancer, although its expression has reported to be associated with
better survival in breast cancer patients treated with adjuvant tamoxifen [86;87].

In the classical pathway of estrogen action, ER alters the expression of target
genes by binding to regions upstream of general promoters known as estrogen response
elements (ERE). This mechanism affects the expression of genes involved in cell growth,
proliferation and differentiation [74;88]. Some examples of target genes containing ERE
sequences are progesterone receptor, lactoferrin, pS2, cathepsin D and BRCAI [88].
When 1713-estradiol (E2) or another estrogenic ligand binds to ER, it induces a
conformational change in the receptor protein leading to dimerization and binding to an
ERE sequence [75;89]. The consensus ERE is a 13 bp palindromic inverted repeat with
the sequence 5'-GGTCAnnnTGACC-3'; however ERa can also bind to imperfect ERE
sequences [88;90;91]. The ERE was first discovered in the 5'-flanking regions of
Xenopus laevis estrogen controlled vitellogenin genes [88;92]. After ERE binding, a
protein complex is formed as either coactivator (e.g. SRC-l, TIFl, TIF2, TFIIB) or
corepressor proteins (e.g. NCoR, SMRT, SHP, REA) bind to the dimer, culminating in
either recruitment of general transcription factors to promote transcription of the adjacent
gene or histone deacetylases to negatively effect ER-mediated transcription [93-96].

Molecular Pathogenesis of Breast Cancer

The progression of breast cancer is a multistep process that involves a series of
genetic changes leading to the conversion of normal cells into carcinoma cells [97]. In
order for normal cells to become cancerous, they must acquire basic traits that include
sustaining proliferative signaling, insensitivity to growth suppressors, evasion of
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apoptosis, replicative immortality, sustained angiogenesis and tissue invasion [97].
Genomic instability

IS

a major underlying cause of normal cells acquiring these

premalignant traits. Genomic instability refers to an increased rate of alterations in the
genome throughout the life cycle of a cell [98]. Normal cells minimize the risk of these
alterations through high-fidelity DNA replication, accurate chromosome segregation
during mitosis, cell cycle checkpoints and repair of DNA damage [99]. Maintenance of
genomic integrity following DNA damage is crucial for tumor suppression. This is
especially important in breast tissue because of the extensive differentiation, proliferation
and apoptosis that occurs during development in utero, puberty, monthly pre-menopausal
cycles and pregnancy [100-102].

DNA damage and repair

DNA damage may be caused by endogenous factors (e.g. oxidative damage,
errors of replication) or environmental factors (e.g mutagenic chemical exposure, food
contaminants, ionizing radiation) [100;103;104]. Among the most dangerous forms of
DNA damage are double strand breaks (DSBs). DSBs occur when both strands of the
DNA double helix are broken simultaneously. This allows the DNA ends to dissociate
making repair difficult and permitting recombination with improper sites in the genome
[105]. As a result, chromosomal aberrations may occur that increase the rate of cancer
development. Therefore, defects in DNA-damage repair pathways are potential initiating
events of carcinogenesis [105-107].
Repair of DSBs occurs through at least two mechanisms: homologous
recombination

and

nonhomologous

end
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joining

[108].

During

homologous

recombination, the DNA strand with the DSB uses an undamaged DNA strand with
which it shares extensive sequence homology as a template [105-108]. Homologous
recombination is generally an accurate mechanism of repair if the template used for
repair is identical to the original DNA sequence [107; 108]. Homologous recombination is
mediated through the RAD52 group of proteins that is composed of RAD50, RAD51,
RAD52, RAD54, RAD55, RAD57, MREll and NBSI [107-110]. Homologous
recombination proceeds by recognition and resection of the DSB ends to form 3'-OH
single-stranded tails, strand invasion and exchange with a homologous DNA duplex and
resolution of recombination intermediates [108; 111].
The first step of homologous recombination involves degradation of the 5'-end of
the DNA strand to produce 3'-OH single-stranded tails that are able to invade a
homologous DNA duplex [108] (Figure 1). The complex of proteins responsible for this
series of reactions is composed of MREll, RAD50 and NBSI (known as the MR(X)N
complex) [109]. In the next step of homologous recombination, one strand of
homologous DNA duplex is displaced by the invasive strand, resulting in the formation
of a heteroduplex DNA known as aD-loop [108;111].

To achieve this, replication

protein A (RP A) first binds to the 3'-OH single-stranded tails, which causes RAD51
filament formation to occur. This filament is a complex of RAD51, RAD52, RAD54,
RAD55 and RAD57 and performs both the search for a homologous sequence and strand
exchange [108;109]. The resulting D-loop is formed when DNA synthesis of the 3'-end
of the invading strand is primed by the template duplex DNA [111]. The last step of
homologous recombination is resolution of the D-loop intermediate. This occurs by one
of three different pathways: synthesis dependent strand annealing (SDSA), double
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Holliday junction (dHJ) or BIR (break induced replication) [109]. In SDSA, the D-loop is
dissolved after DNA synthesis allowing the invading strand to anneal to the second end
of the DSB [lOS]. In dHJ, pathway a double Holliday junction is formed when the second
end of the DSB is occupied by either DNA annealing or a second strand invasion [108].
BIR occurs when only a single DSB end exists causing the D-loop to become a
replication fork [109]. The breast cancer susceptibility genes, BRCA 1 and BRCA2, also
function in HR. BRCAI is an E3 ligase that promotes RADSI recruitment and has a
potential regulatory role in resection of the DSB ends [109; 112]. BRCA2 is involved in
RADSI filament formation [109]. By interacting with both RADSI and single-stranded

DNA, BRCA2 mediates the binding ofRADSI to damaged DNA [113].
Nonhomologous end joining (NHEJ) ligates two DSBs without the need for
extensive sequence homology between the two ends [lOS]. This results in NHEJ being
inherently error prone with the potential result of loss of nuc1eotides [114]. NHEJ
proceeds by detection of the DSB, protection of the DNA ends, removal of damage and
DNA ligation [114]. The major proteins involved in this pathway are Ku70, KuSO, DNAdependent protein kinase (DNA-PK), Artemis, XRCC4, ligase IV and XLF/Cernunnos
[114-116]. The first step in NHEJ is recognition of the DSB by the Ku protein complex,
which is composed of a heterodimer of Ku70 and KuSO (Figure 2) [103;114;l1S;117].
Ku70 and KuSO make up the DNA-binding subunits of DNA-PK. After binding to the
DNA ends, Ku translocates to internal positions of the DNA molecule making the ends
accessible to the catalytic subunit of DNA-PK (DNA-PKcs) [l1S-120]. DNA-PKcs is a
460-kDa serine/threonine kinase that is part of the phosphotidylinositol-3-kinase family
[114;117;121]. Then the two DNA ends are tethered together by a synaptic complex
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Figure 1. Steps in the homologous recombination pathway. (A) Damage in the form of a
DSB occurs in the DNA. (B) The first step of homologous recombination is binding of
the MR(X)N complex to the DSB. (C) Degradation of the 5'-end of the DNA strand
occurs to produce 3'-OR single-stranded tails that are able to invade a homologous DNA
(d) Replication protein A (RPA) binds to the 3'-OR single-stranded tails, which causes
RAD51 filament formation to occur (E). (F) The resulting D-Ioop is formed when DNA
synthesis of the 3'-end of the invading strand is primed by the template duplex DNA (G)
The last step of homologous recombination is resolution of the D-Ioop intermediate and
repair of the DNA. Adapted from [108].
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formed by two DNA-PK molecules [122]. Subsequently, the kinase activity of DNAPKcs is activated causing an autophosphorylation across the DSB as well as
phosphorylation of other proteins involved in NHEJ [114;123-127]. This allows other
NHEJ proteins to bind to the DNA ends [124;128]. The next step in NHEJ is processing
of the DNA ends by nucleases such as Artemis. Artemis is a 5'~ 3' exonuclease that also
exhibits endonuclease activity in the presence of DNA containing double-stranded
DNA/single-stranded transitions [129;130]. Artemis also possesses the ability to remove
3'-phosphoglycolate groups from DNA ends [131].
The final step in NHEJ is ligation of the DNA ends by the DNA ligase
IV /XRCC4 complex. XRCC4 acts a scaffolding protein that is required for DNA ligase
IV activity [132-134]. DNA ligase IV ligates the DNA ends, even if the sequences are
incompatible [135]. XLF associates with Ku and XRCC4 and increases the ability of
DNA ligase IV to achieve this [136]. The recruitment ofDNA-PKcs, XRCC4 and XLF is
dependent on Ku [137-139].

Structure and function ofKu

Ku was originally identified as an autoantigen present in the sera of a patient with
scleroderma polymyositis overlap syndrome [140]. It has also been identified in patients
with other autoimmune diseases such as systemic lupus erythematosus, scleroderma,
myositis and Sjogren's syndrome [141]. Ku is an abundant protein

(~400,000

molecules

per cell) that is primarily nuclear [103;142]. Ku has also been found in the cytosols of
monkey and human cells [143;144]. The Ku protein is composed of two subunits with
molecular weights of approximately 70 and 80 kDa, referred to Ku70 and Ku80. Ku70 is
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Figure 2. Steps in the nonhomologous end joining pathway. (A) Damage in the form of a
DSB occurs in the DNA. (B) The first step in NHEJ is recognition of the DSB by the Ku
protein complex, which is composed of a heterodimer of Ku70 and Ku80. (C) Ku
translocates to internal positions of the DNA molecule making the ends accessible to
DNA-PKcs. (D) Two DNA ends are tethered together by a synaptic complex formed by
two DNA-PK molecules. (E) The kinase activity of DNA-PKcs is activated causing an
autophosphorylation across the DSB. (F) This allows other NHEJ proteins to bind to the
DNA ends such as Artemis, the DNA ligase IVIXRCC4 complex and XLF. (G) The final
step in NHEJ is ligation of the DNA ends. Adapted from [114].
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also known as XRCC6 and Ku80 is also known as Ku86 and XRCC5.
Ku70 and Ku80 are similar in structure but share only 14% sequence alignment
[145]. Each contains a von Willebrand A domain (vWa), a central Ku core domain and a
carboxy-terminal region [142] (Figure 3). The vWa domain is involved in protein-protein
interactions and Ku70 and Ku80 heterodimerization. The Ku core domain is a

~-barrel

domain that binds to the sugar-phosphate backbone of DNA [146]. The N-and C-terminal
regions of Ku70 and Ku80 are unique in each protein. In addition, the N-terminal region
of Ku70 is an acidic domain that contains a DNA-PKcs phosphorylation site [123]. The
C-terminal region of Ku70 contains a SAP (SAF-A/B, Acinus and PIAS) domain which
is related to a helix-extension-helix fold and is proposed to be a DNA-binding domain
[147;148]. The C-terminal region of Ku80 is longer than Ku70 and forms a flexible arm
possibly involved in protein-protein interactions [149; 150]. This region also contains a
DNA-PKcs binding site and phosphorylation site [151;152]. Furthermore, Ku70 contains
a nuclear localization sequence (NLS) at amino acids 539-556 and Ku80 contains a NLS
at amino acids 561-569 [153;154].
The heterodimer of Ku70 and Ku80 forms an asymmetric ring that encircles
dsDNA [145]. The channel formed by this ring contains positively charged residues that
are responsible for the interaction between the protein and the sugar-phosphate DNA
backbone. This structure allows Ku to bind DNA with high affinity and without the need
for sequence specificity [142]. It is reported that this structure allows Ku to move inward
along the DNA strand making the DNA ends accessible to DNA-PKcs [120].
The main function of Ku is in NHEJ as described above; however it also functions
in V(D)J recombination, telomere maintenance, apoptosis and regulation of transcription
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Ku70

NLS

amino acids

Figure 3. Structural features of Ku70 (A) and Ku80 (B). Each protein contains a von
Willebrand A domain (vWa), a central Ku core domain and a carboxy-terminal region
(CT). The N-and C-terminal regions of Ku70 and Ku80 are unique in each protein. For
example, the C-terminal region of Ku70 contains a SAP (SAF-AlB, Acinus and PIAS)
domain which is related to a helix-extension-helix fold and is proposed to be a DNAbinding domain. In addition, the C-terminal region of Ku80 contains a DNA-PKcs
binding site. Ku70 contains a nuclear localization sequence (NLS) at amino acids 539556 and Ku80 contains a NLS at amino acids 561-569 [114;142;154].
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[142;146;155]. In V(D)J recombination, different V, D, and J genes segments are joined
together in various combinations generating diversity in immunoglobulins and T-cell
receptors. During recombination, a hairpin structure with blunt double-stranded ends is
formed. Ku is recruited to this structure to repair the double-stranded ends in a manner
similar to NHEJ [142;156;157].
Telomeres are G-rich DNA sequences located in the ends of chromosomes of
eukaryotes that function to prevent chromosome fusion and protect the chromosome from
deterioration. Ku binds to telomeric sequences during telomere repair and helps prevent
end-to-end DNA fusion through association with telomerase reverse transcriptase [158160]; however the exact mechanism for this is unclear. In S. cerevisiae, Ku localizes
telomeres to the nuclear membrane and is part of the complex that is required for
transcriptionally silent chromatin [161;162]. S. cerevisiae deficient for Ku have telomeres
shorter in length than wild type strains [163]. Loss of one Ku80 allele in human cells
results in shorter telomere length and increased genomic instability [142].
Cytosolic Ku70 has been shown to be involved in apoptosis through its
association with Bax. Bax is a member of the Bcl-2 family of pro-apoptotic proteins that
regulate apoptosis through control of the integrity of mitochondria. Ku70 binds Bax
preventing its localization to the mitochondria thereby inhibiting apoptosis [144]. This
activity is mediated by a region in the carboxy terminus of Ku70 and does not require
heterodimerization with Ku80. Upon apoptotic stress, Bax dissociates from Ku70,
undergoing a conformational change followed by translocation to mitochondria and
subsequence apoptosis [144; 164].
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Ku also appears to be involved in the regulation of transcription of certain genes.
Some reports suggest that Ku binds in a sequence-specific manner to the promoters of
heat shock proteins, glucose-regulated peptide 78 and glucose-regulated peptide 94, and
regulates the transcription of these genes [165-167]. However, these studies used linear
DNA, raising the possibility of the DNA ends playing a role in sequence binding.
Because of the ring like structure of Ku, sequence specific binding in vivo would most
likely occur through the formation of unusual DNA structures, although binding could
also occur through the carboxy-terminal SAP domain of Ku70 [148;165;168]. Other
reports have shown that Ku is involved in transcriptional regulation without sequence
specific binding. For example, Ku associates with RNA polymerase II elongation sites
through protein-protein interactions between Ku80 and transcription-elongation proteins.
However the mechanism by which Ku regulates transcription is unclear [169].

Preliminary Results
Hormone Receptor Laboratory TumorMarker Database and biorepository:

The studies outlined in this dissertation utilized de-identified human tissue
specimens and associated clinical data available in the IRB-approved Hormone Receptor
Laboratory (HRL) Biorepository and Tumor Marker Database. Tissue specimens were
collected and typically processed within an hour following surgery using stringent
protocols to ensure the integrity of specimens for genomic and proteomic analyses
[20;24]. Remaining tissue was stored at -80°C from over 5,000 breast, ovarian, uterine
and colon cancers, of which specimens were selected for these studies. The HRL
Biorepository and Tumor Marker Database contain associated de-identified tumor
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marker/clinical outcome that includes up to 15 years of clinical follow-up. Available
clinicopathological data include tumor-based properties (e.g., pathology, grade, stage,
size and tumor marker status), patient-related characteristics (e.g., age, race, menopausal
status, family history, nodal status) and clinical follow-up (e.g, treatment regimen,
disease-free and overall survival). As a state and federally licensed clinical laboratory, the
HRL performed biochemical assays measuring the protein levels of ER and PR for
~22,000

human tissue specimens, most of which were breast cancers. Quantitative ER

and PR expression (fmol/mg cytosol protein) data were generated using two different
FDA-approved clinical assays described earlier: ligand binding assay (LBA) and enzyme
immunoassay (EIA, Abbott Technologies).

Detection of ERE-BP in breast cancer tumor extracts

While investigating DNA-binding properties of ERa in breast cancer cytosols, we
discovered non-ERa proteins that recognized ERE sequences [170-172]. To determine
the distribution of these ERE-binding proteins (ERE-BP), cytosols were prepared as
previously described [20;37;168] from various breast cancer biopsies and analyzed by
electrophoretic mobility shift assay (EMSA) using a

eP]labeled
2

Xenopus laevis

vitellogenin A2 (VitA2) ERE, which contains a perfect palindrome sequence [88;173].
Four types of expression profiles of the ERE-BP were detected with band migration
distances appearing lower than that of recombinant human ERa (rhERa) which served as
a control ERE-binding protein (Figure 4).
The most common profile (63% of samples) consisted of a single band on an
EMSA gel migrating below that of rhERa. A few cytosols exhibited a band migrating
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Figure 4. Distribution of ERE-binding proteins in breast cancer cytosols. Cytosols were
prepared as previously described [20;38;39; 174] from various breast cancer biopsies and
analyzed by electrophoretic mobility shift assay (EMSA) using a

eP]labeled Xenopus
2

laevis vitellogenin A2 (VitA2) ERE (Lanes 2-14). Recombinant human ERa (rhERa)

served as a control ERE-binding protein (Lane 1). Equal amounts of protein (13 )lg) were
loaded in each lane.
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lower than the major ERE-BP band (4% of the samples examined) while a significant
number of EMS A profiles contained both bands (24%). Nine percent of the samples were
negative for ERE-BP. To detennine if the presence of the ERE-BP is related to ER or PR,
levels were correlated with the ER and PR status of the tumor (Figure 5). The DNAbinding levels of ERE-BP present in breast cancer cytosols were detennined by scanning
each lane of the EMSA gels and using Optiquant™ software for quantification. Patients
were grouped according to ER and PR status and data were analyzed by box and whisker
plots followed by a Kruskal-Wallis test. No correlation was found between ERE-BP level
and ERJPR status suggesting these proteins are unrelated to the nuclear sex honnone
receptor proteins.
To confinn that the observed complex fonned is a DNA-protein complex, protein
extracts were treated with pepsin, trypsin and RNaseA prior to ERE-binding reactions
and analyzed by EMSA (Figure 6). Treatment with 100
binding of ERE-BP to the ERE. Treatment with 100
smaller ERE-BP fragment. Treatment with 100

~g/ml

~g/ml

~g/ml

pepsin at 37°e eliminated

pepsin at 4°e resulted in a

trypsin at both 4°e and 37°e

eliminated binding of the ERE-BP to the ERE. Treatment with 100

~g/ml

RNase A had

no effect on complex fonnation at either 4°e or 60 o e. Addition of 0.01 % SDS to the
reaction mixture and boiling also eliminated binding. These results confinn that the
complex observed is indeed a DNA/protein complex.
To detennine if these ERE-BP have prognostic significance for patients with
breast carcinoma, Kaplan-Meier survival analyses were perfonned (Figure 7). Patients
were divided into ERE-BP negative or ERE-BP positive groups and overall survival
probabilities were examined [172]. At 100 months of follow-up, patients with tumors

23

s:::

0

>. "(5

~O
> ...
;c.

~ ~-1
0)-

g>
=c=c
s::: s:::
s:::

iii
I

:c

-2

n=363
p=O.379

<Ccfe.
Z

0

Co;

-~ -3~--~------~------r-----~~-
ER+/PR+ ER-/PR+

ER-/PR+

ER-/PR-

Figure 5. Correlation of ERE-BP binding activity with ER and PR status. The DNAbinding levels of ERE-BP present in breast cancer cytosols was determined by scanning
each lane of the EMSA gels and using Optiquant™ software for quantification, expressed
as 10glO % binding/J..lg protein. Patients were grouped according to ER and PR status and
data were analyzed by box and whisker plots followed by a Kruskal-Wallis test.
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Figure 6. Effect of enzymatic digestion on ERE-BP. Cytosols containing ERE-BP were
treated with either 100 Ilg/ml pepsin, 100 Ilg/ml trypsin, 100 Ilg/ml RNase A at the
temperatures indicated, boiling at 95°C for 5 minutes or 0.01 % SDS prior to the binding
reaction and analyzed by EMSA. The untreated control cytosol (C) is also shown.

25

1.1
c
0

:;::;

u

co
"-

LL

co

>

'~

:::l

(J)

1.0
ERE-BP ~tga lh't

0.9

0.8
0.7
ERE-DP Posilh't

0=229

0.6

,FO.058

0.5
0

50
100
OVerall Survival (months)

150

Figure 7. Overall survival probabilities of breast cancer patients as a function ofERE-BP
status. Kaplan-Meier analyses were used to determine the influence of ERE-BP status
(either positive or negative) on overall (OS) survival. P values were determined using a
log-rank test.
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that were ERE-BP negative had survival probabilities of 90%, while patients with tumors
that were ERE-BP positive had survival probabilities of only 68%, suggesting that these
proteins may be prognostic markers for breast cancer.

Hypothesis and Specific Aims
The overall goal of these investigations is to characterize and identify these novel
proteins that were first detected by their recognition of ERE sequences and confirm their
clinical relevance in a larger patient population as a result of our initial detection of the
proteins in human breast cancers.

The hypothesis for these investigations is that the ERE-binding protein identified
in human breast cancer biopsies functions independently of estrogen receptor signaling
and their DNA-binding activity correlates with breast cancer prognosis. This hypothesis
will be examined in the following Specific Aims:

Specific Aim I - To determine the biological characteristics of the novel ERE-BP (e.g.
sequence specificity, effect ofER ligands, tissue distribution, cellular localization).

Specific Aim II - To purify the ERE-BP using immunobased methods and identify their
sequences by mass spectrometry.

Specific Aim III - To correlate ERE-BP expression and activities with properties of the
breast carcinoma (e.g. pathology, stage, nodal status), patient characteristics (e.g., family
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history, age, race), and clinical outcome (disease-free and overall survival) to determine
clinical relevance of ERE-BP status for prediction of a patient's prognosis and the
clinical behavior of the breast carcinoma.
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CHAPTER II
CHARACTERIZATION AND DISTRIBUTION OF CANDIDATE ESTROGEN
RESPONSE ELEMENT BINDING PROTEINS IN HUMAN BREAST
CARCINOMA

Introduction

The focus of the studies described in this Chapter is to investigate the distribution
and biochemical properties of the newly discovered ERE-binding proteins [172].
Preliminary studies in our laboratory suggested these ERE-binding proteins (ERE-BP) in
cytosols were associated with breast cancer behavior and characteristics prompted this
series of experiments. Our initial results revealed four types of expression profiles of
ERE-BP on EMSA with band migration distances greater than that of recombinant
human ERa (rhERa) and DNA-binding activities of ERE-BP were not correlated with
levels of either ER or PR in extracts from breast cancer specimens, although patients with
breast cancers that were ERE-BP negative exhibited decreased overall survival.

Known ERE-binding proteins

A number of proteins other than the estrogen receptor have been reported to bind
to ERE sequences. Orphan receptors such as the estrogen related receptors (ERR) bind to
the ERE and affects estrogen signaling either positively or negatively [175;176]. ERRa
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binds to the ERE sequence in the human lactoferrin gene promoter and constitutively
activates transcription [177]. ERRa also competes with ERa for binding to consensus
ERE sequences and either acts as a constitutive activator or as an active repressor of
ERE-regulated transcription in a cell type-dependent manner [178]. These results suggest
the need for evaluation methods capable of characterizing more subtle aspects of EREprotein interactions in any given tissue sample. Another orphan receptor, COUP-TF, also
has been shown to bind to ERE sequences and inhibit estradiol induced gene expression
[179-181 ].
In addition to the estrogen-related and orphan receptors, other proteins have been
reported to compete with ERa for ERE binding [182-186]. In New World primate cells,
ERE-binding proteins were discovered that compete with human estrogen receptor for
binding to the consensus ERE [183]. These endogenous ERE-BP were able to block
ERE-mediated transcription in marmoset B-Iymphoblastoid B95-8 and owl monkey
kidney cells. Chen et al. determined that the protein responsible for this activity was
similar to the hnRNP C-like or hnRNP-D subfamily of heterogeneous nuclear
ribonucleproteins and that its overexpression results in estrogen unresponsiveness in
primates [183;184;186]. More recently, Chen et al. showed that overexpression of these
ERE-binding proteins in MCF -7 cells resulted in dysregulation of normal interactions
between ERa and the ERE [185] and that estradiol and tamoxifen could restore the
normal interaction [186].
Another ERE-binding protein has been identified in cytosols of rat uteri that may
influence ER binding [187]. Expression of this protein was detected in both estrogen
responsive and nonresponsive tissues and injection with
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17~-estradiol

repressed the ERE-

BP levels by 40-50%. UV crosslinking experiments revealed that the molecular weight of
the protein to be 48 kDa, however the identity of the protein was never discovered.
The purpose of this investigation was to characterize proteins observed in breast
tumor extracts that bind to ERE sequences in order to determine their role in breast
cancer behavior. The goal was to determine if these proteins share properties with ERa,
ERP or with other known ERE-binding proteins discussed above.

Methods and Materials

Preparation o/human recombinant estrogen receptor-a (rhERa) protein

The yeast strain BJ3505 was transformed with an hERa expression plasmid YEpE12 and
hERa is expressed as an ubiquitin fusion under the control of CUP 1 promoter [188;189].
Yeast

cells

were

grown

III

complete

(-Trp)

medium

and

monitored

spectrophotometricallyat a wavelength of 595 nm. When the OD595 reached 0.6, rhERa
expression was induced by addition of CUS04 to a final concentration of 100

~M.

After

harvesting and washing with water, yeast pellets were extracted in 40 mM Tris buffer
with 1.5 mM EDTA, 10% glycerol, 10 mM Na2M004, 10

~M

monothioglycerol and 1

mM PMSF. Yeast cells were disintegrated with glass beads in a Vortex Genie® in 5
intervals of 30 seconds each, with 30 seconds intervals cooling on ice. Debris was
removed from the preparation by centrifugation at 100,000 x g for 30 minutes at 4°C. The
supernatant containing rhERa was recovered for immediate assay or stored at -80°C for
future use as a reference representing a well characterized ERE-binding protein.
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Cytosol preparation

Cytosols were prepared from de-identified human breast cancer tissue specimens in 40
mM Tris-HCI, pH 7.4, containing 1.5 mM EDTA, 10% glycerol, 10 mM Na2Mo04, 1
mM PMSF and 10

~M

monothioglycerol, and homogenized with a Polytron PT-I0-35.

Homogenate was separated into pellet and cytosol by centrifugation at 105,000 x g for 30
minutes at 4D C, using a Beckman LE-80K ultracentrifuge [20;38;39;60;174]. Protein
concentration of each cytosol was determined by the Bradford procedure [190]. Cytosols
were stored at -80 D C for future use.

Nuclear extract preparation

Tissue sections were prepared in a nuclease and protease-free environment using a Leica
cryostat/frozen microtome [191]. For preparation of nuclear extracts, ten 30

~m

frozen

tissue sections were placed into pre-chilled 1.5 mL microcentrifuge tubes and
immediately stored on dry ice. Sections were transferred to a chilled Duall homogenizer
and homogenized in 10 mM HEPES buffer, pH 7.9, containing 10 mM KCI, 0.1 mM
EDTA,1 mM DTT, 0.5 mM PMSF with aprotinin, leupeptin and pepstatin A (0.01

~g/~l

each). Lysates were centrifuged at 4°C at 15,000 x g for 3 minutes. The nuclear pellet was
resuspended in 20 mM HEPES, pH 7.9 containing 0.4 M NaCl, 1 mM EDTA, 10%
glycerol, 1 mM DTT, 0.5 mM PMSF with aprotinin, leupeptin and pepstatin A (0.01
~g/~l

each). The resuspended pellets were mixed at 4°C for 2 hours and centrifuged at

4°C, 15,000 x g for 5 minutes [192;193].
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Labeling of ERE sequences

For labeling with

ep]dATP,
2

30 J!M synthetic double-stranded ERE sequences

(Integrated DNA Technologies) were incubated with Klenow DNA buffer (Promega), 5%
~-mercaptoethanol

(Sigma), 750 J!M dCTP, dGTP, and dTTP (Promega), 1.25 J!M

[a32 P]dATP (Perkin Elmer) and 5 units DNA Polymerase I Large (Klenow) fragment
(Promega) at 37°C for 30 minutes, followed by a gravity-flow separation through a NICK
column (Amersham). The sample was eluted with 3 ml TE buffer (10 mM Tris-HCl, pH
8.0, containing 1 mM EDTA) and collected into fractions (-100 J!l each). Radioactivity
was measured by a scintillation counter and fractions were also run on a 4%
polyacrylamide gel to confirm the presence and separation of labeled ERE from
unreacted

ep]dATP [188;194]. Representative results are shown in Figure 8.
2

Electrophoretic mobility shift and supershift assays

Protein extracts were incubated with 50 ng non-specific DNA, poly (dl-dC) (Amersham),
10 mM KCl, 1% glycerol and

eP]-labeled ERE sequences in 40 mM Tris-HCl buffer,
2

pH 8.0, containing 500 J!M PMSF and 10 J!M monothioglycerol overnight at 4°C. In ERE
competition experiments, a 125-fold molar excess of unlabeled ERE was added to each
reaction and incubated for 30 minutes before addition of

ep]ERE [195]. Sequences used
2

are shown in Table 8 (See Appendix). For supershift assays, extracts were incubated with
various antibodies for 30 minutes before addition of

ep]ERE. Reactions were separated
2

by 5% polyacrylamide gel electrophoresis. The gel was pre-run for 30 minutes at 150 V
at 4°C in 0.5X TBE buffer (1.0 M Tris-HCl, pH 8.6, containing 831 mM boric acid, 10
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(A) Example of a profile of

C2P]VitA2 ERE sequence separated from unreacted C2p]dATP using a Nick column. The
sharp peak at fractions 3-5 indicate the labeled ERE and the second, broad peak
represents the free

C2P]dATP.

Here fraction #4 is the most active and ideal for use in

EMSA experiments. (B) NICK column fractions were subjected to electrophoresis on a
4% polyacrylamide gel. The slower moving bands (Lanes 3-5) represent labeled

C2p]VitA2-ERE, while the faster migrating bands (Lanes 7-15) represent free C2p]dATP.
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mM EDTA). Samples were then loaded, followed by electrophoresis at 300 V for 5
minutes, and then 180 V for 4 hours. Subsequently, gels were dried and exposed to
phosphor screens (Perkin Elmer) overnight. The bands representing
complexes and free

ep]ERE-protein
2

ep]ERE were visualized and quantified using a Cyclone Storage
2

Phosphor System with OptiQuant® software (Perkin Elmer).
A method of estimating the DNA binding activity levels of ERE-BP in breast
cancer biopsies was developed by measuring the band intensity of the ERE-BP/ERE
complexes or free

ep]ERE in each lane from the EMSA using OptiQuant® software.
2

The value of band intensities (representing the amount of

eP]Vita2-ERE ) are reported
2

as Digital Light Units (DLU)lllg protein and normalized to the total DLU of the lane in
order to compare between samples. A representative band quantification experiment is
shown in Figure 9.

ERE titrations of ERE-binding proteins

EMSAs were performed as described above with varying amounts of

ep]VitA2-ERE
2

and a constant 51lg of total protein. The reactions were incubated with either ethanol
(ETOH) or 1 IlM diethylstilbesterol (DES), 4-hydroxytamoxifen (Tmx),
(E2) or raloxifene (Rlx) for 30 minutes before the addition of

17~-estradiol

ep]Vita2-ERE. Gels were
2

scanned and bands quantified using OptiQuant® software as previously described. A
standard curve plotting fmoles of ERE versus DLU was used to determine the amount of
ERE bound by protein. Data were modeled using one-site binding kinetics with
GraphPad Prism® software.
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Figure 9. Method for estimating ERE-binding protein activities in breast cancer biopsies

ep]VitA2-ERE. A representative profile of an EMSA gel is visualized using the
Cyclone Phosphoimager and the total DLU representing total ep]VitA2-ERE

using

2

2

radioactivity in a single lane of the EMSA gel is measured in A. After outlining each lane
as shown in A, the DLU for each band (ERE-BP or rhERu) are determined by integrating
the area under the curve using Optiquant™ software (B).
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Results and Discussion
Distribution of ERE-binding proteins in various tissues

To assess the tissue specificity of ERE-binding proteins, extracts of several
human tissue reference powders prepared from breast cancer, fibroid, uterus and
myometrium were analyzed by EMSA after incubation with ERE sequences for the
vitellogenin gene (VitA2) and the pS2 gene. These reference powders were prepared
previously as standards for assessment of estrogen and progestin receptor activities used
in clinical trials for human breast cancer [25;26]. Cytosols from reference powders of
breast cancer, uterus and fibroids exhibited prominent bands suggesting high
concentrations of the ERE-binding proteins recognizing these two

ePJERE sequences
2

(Figure 10). The myometrial cytosol only displayed a very low quantity of these proteins
when the same amount of total protein was examined by EMSA. Each of the ERE-BP
migrated to a position on EMSA gels lower than that of rhERu. Cytosols prepared from
frozen ovarian, colon and endometrial carcinomas as well as normal uteri were also
analyzed for the presence of ERE-BP (Figure 11). Cytosols from these tissues exhibited
prominent bands suggesting high concentrations of the ERE-binding proteins recognizing

ePJVitA2-ERE sequences, indicating that the ERE-BP are ubiquitous proteins present in
2

a variety of tissues.
To examine species specificity of the ERE-binding proteins, extracts from uteri of
rat, calf, and ververt monkey (Cercopithecus aethiops) also were analyzed by EMSA
with the

ePJERE sequences for the VitA2 and pS2 genes (Figure 10). rhERu was used
2

as a control on the EMSA gels to show that ERE-binding proteins migrated below the
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Figure 10. ERE-binding proteins from extracts of human tissue reference specimens and
animal tissues associated with VitA2-ERE (A) and pS2-ERE (B). To assess tissue
specificity, extracts of human tissue specimens prepared from a pooled preparation of
either de-identified breast cancer (Lane 1), fibroids (Lane 2), uteri (Lane 3) and
myometria (Lane 4) were analyzed by EMSA with

C2PJERE sequences for the VitA2 and

pS2 genes. To evaluate species specificity of ERE-BP, uteri of rat (Lane 5), calf (Lane 6)
and ververt monkey (Cercopithecus aethiops) (Lane 7) were also analyzed. rhERa served
as a control (Lane 8). Total protein in a quantity of 17 ug was added in each lane.
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Figure 11. ERE-binding proteins from extracts of frozen human tissue specimens
associated with VitA2-ERE. Cytosols of human tissue specimens prepared from either
de-identified ovarian carcinoma (A), endometrial carcinoma (B), normal uteri (C) and
colon carcinoma (D) were analyzed by EMSA with

ePJERE sequences for the VitA2
2

genes. rhERa served as a control as indicated. Total protein in a quantity of 25 ug was
added in each lane.
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band position representative of the estrogen receptor protein. It was noted that rhERa
recognized

ep]VitA2 ERE with a higher apparent affinity than that of pS2 ERE.
2

Neither cytosol from rat or calf uteri exhibited significant quantities of ERE-binding
proteins, although ververt monkey uterine extracts expressed high levels of two distinct
ERE-binding protein species migrating below rhERa (Figure 10).
As mentioned previously, other investigators have identified proteins recognizing
the ERE sequence in New World primate B95-8 and owl monkey kidney cells [182;183].
Further characterization by these investigators revealed these proteins belong to the
hnRNP family. This suggests the proteins identified in our investigations that are
expressed in ververt monkey tissue may also be members of this family, which prompted
our use of supershift assays using antibodies against these proteins as described below.

Cellular distribution ofERE-BP

To determine the cellular distribution of ERE-BP, levels were compared between
cytosolic and nuclear extracts by EMSA. Extracts from various human tissue reference
samples were prepared as described above and equal amounts of total protein were used
in each of the EMSA reactions. We evaluated a variety of fresh frozen and lyophilized
breast and uterine preparations that had been composed to serve as reference specimens
for quality assurance surveys of ER and PR [25;26]. Results of these human tissue
reference specimens are shown in Figure 12A. The DNA-binding activities of the EREBP varied in both the cytosolic and nuclear extracts in each tissue sample analyzed.
Generally the nuclear extracts exhibited a higher DNA-binding activity of the ERE-BP
than those in cytosolic extracts. We also evaluated ERE-BP in de-identified frozen breast
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cancer biopsies. As shown in Figure 12B, the nuclear extracts of three different breast
carcinomas contained significantly higher ERE-BP levels than those of cytosolic extracts
of these representative specimens.
These results consistently reveal a higher abundance of these ERE-binding
proteins in the cell nucleus than in the cytoplasm. Chen et al. also reported finding EREbinding proteins belonging to the hnRNP family in nuclear extracts [182] while Gray and
Gorski reported finding ERE-binding proteins in cytosols [187]. Identification of the
ERE-BP we have observed is necessary to determine whether these proteins are the same
as those previously reported or if they represent new candidate biomarkers of breast
cancer behavior.

Lack of recognition ofERE-BP by antibodies against ERa and ERfJ

Super-shift assays were performed to determine if ERE-BP contain epitopes
recognized by antibodies prepared against various regions of the human ERa protein
(e.g., AER 320/C-terminus, AER314/a.a. 125-165, ID51N-terminus, 5Dll1a.a. 302-553)
or

ER~

(e.g. MAI-310/a.a. 247-261, PAI-311/a.a. 55-70, PAI-313/a.a. 467-485). The

epitope for AER611 is unknown. As shown in Figure 13, rhERa exhibited a supershift
when reacted with each antibody, verifying its identity; however, ERE-BP did not
supershift in the presence of anti-ERa antibodies recognizing different ERa epitopes.
Reaction of

rhER~

with antibodies recognizing epitopes of the various regions in the

receptor protein brought about supershifts with most of the reagents. The basis for the
lack of recognition of Ab-15 is unknown; however,
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cytosolic and nuclear extracts. To

determine the cellular distribution ofERE-BP, activities were compared between those of
cytosolic and nuclear extracts using

ep]VitA2-ERE and EMSA. Extracts from various
2

lyophilized human tissue reference samples were prepared as cytosol (C) and nuclear
extracts (N) as described in Materials and Methods. Equal amounts of total protein (25
Jlg) were used in each of the EMSA reactions. The de-identified preparations examined
were either breast carcinoma (pairs 1, 4 and 7) or uterine tissues (pairs 2, 3, 5 and 6) as
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Figure 13. Influence of hERa antibodies recognizing different sequence domains on the
cytosolic ERE-BP assessed by super-shift assay. Recombinant hERa (A) and cytosol
from a human breast cancer reference specimen containing ERE-BP (B) were incubated
with hERa specific antibodies AER 314, 320, 611 , IDS and SD11 (NeoMarkers/Thermo
Fisher) recognizing epitopes in various domains of ERa (e.g., AER 320/C-terminus,
AER314/a.a. 12S-16S, IDS/ N-terminus, SDII/a.a. 302-SS3)
(PanVeraiLife Technologies).
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Figure 14. Influence of hER!) antibodies recognizing different sequence domains on
cytosolic ERE-BP assessed by super-shift assay. Recombinant hER!) (PanveraiLife
Technologies) and cytosol from a human breast cancer reference specimen were
incubated with hER!) specific antibodies Ab-15 (Neomarkers/Thermo Fisher), MA 1-31 0,
PAl-310, PAl-311 and PAI-313 (Affinity Bioreagents/Thermo Fisher) recognizing
epitopes in various domains of hER!) (e.g. PA1-3l1/a.a. 55-70, MAl-3l0/a.a. 247-261 ,
PAl-3l0/a.a. 467-485, PAl-313/a.a. 467-485).
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Figure 15. Supershift assay using antibodies to known ERE-binding proteins. Supershift
assays were performed on cytosols from a breast cancer reference specimen with
antibodies to known ERE-binding proteins. Lane 1 shows the ERE-BP control. Lane 2:
hnRNP D (GenWay), Lane 3: hnRNP DL (GenWay), Lane 4: hnRNP ClIC2 (Santa
Cruz), Lane 5: ERRa (R&D Systems), Lane 6: COUP-TFI (R&D Systems).
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PAI-310 which may block binding of the receptor to

ep]ERE (Figure 14). Figure 14
2

also shows that ERE-BP did not supershift in the presence of anti-ERp antibodies.

Supershijt assay using antibodies to known ERE-binding proteins
To evaluate whether ERE-BP were recognized by antibodies to other known
ERE-BP, supershift assays were performed using antibodies prepared against hnRNP D,
hnRNP DL, hnRNP CIfC2, ERRa and COUP-TFI (Figure 15). No supershifts were
observed when breast cancer cytosols were incubated with antibodies to either hnRNP D,
hnRNP DL, hnRNP ClIC2, ERRa or COUP-TFI (Figure 15), suggesting that the
proteins of interest are not related to members of the hnRNP family or to COUP-TF.
These results suggest that the ERE-binding proteins we have identified are not
among the more commonly known ERE-binding proteins. However, supershift assays are
not definitive for protein recognition due to the nature of the non-denaturing conditions
of EMSA. The native conformation of a protein may leave certain epitopes inaccessible,
thereby preventing antibody recognition. Therefore, more definitive results are needed to
determine and confirm the identity of these ERE-BP.

ERE-BP and ERa. compete for ERE binding
To ascertain if ERE-BP influence ERE recognition by rhERa, competition
experiments were performed by incubating increasing quantities of cytosol from both an
ERE-BP positive and an ERE-BP negative tissue, with constant concentrations of rhERa
and VitA2-ERE (Figure 16A). Band intensities of both the ERE-BP and rhERa proteinDNA complexes were determined by scanning the gel lanes and integrating the areas
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Figure 16. Competition ofrhERa recognition ofVitA2-ERE by ERE-BP in human breast
cancer extracts. Competition experiments were performed by incubating increasing
quantities of cytosol from either an ERE-BP positive (Lanes 1-7) or negative extract
(Lanes 9-15), holding the concentrations of rhERa and

ep]VitA2-ERE constant (A).
2

Lanes 1 and 15 contained extract only. Lane 8 contained only rhERa.
concentration of rhERa in

~g/reaction

The protein

was plotted against ERE-binding expressed as a

percent of the rhERa control (B, . ). The binding isotherm for the ERE-BP was plotted
similarly (B, 0).
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under the curves for each band, usmg Optiquant@ software. Protein concentration
(~g/reaction)

was plotted against ERE-binding as percent of control for either rhERa or

ERE-BP, showing an expected sigmoidal dose-response curve (Figure 16B). An ERE-BP
positive reference cytosol inhibited hERa binding to VitA2-ERE in a concentrationdependent manner with simultaneous appearance of the novel ERE-BP. These results
confirm that the observed suppression of rhERa binding to ERE results from the presence
of ERE-binding proteins, indicated by lack of competition by an ERE-BP negative
extract (Figure 16A).
Other studies have reported that an ERE-binding protein can compete with the
estrogen receptor for binding to ERE sequences. Kraus et al. reported that ERRa
competes with ERa for binding to ERE sequences in MCF-7 breast cancer cells [196].
However, ERRa binding to the ERE alone was not sufficient to mediate transcription.
Burbach et al. reported that COUP-TFI competes with ERa for binding to the ERE and
this was sufficient to repress transcription of the oxytocin gene in P19 embryonal
carcinoma cells [179]. Furthermore, Chen et al. reported that the ERE-BP discovered in
New World primate cells that appear to be related to hnRNPs can also compete with ERa
for binding to the ERE and disrupt the ERIERE interaction [182]. Competition results
correlated with the amount ofERE-BP present in the extract.

Sequence binding specificity ofERE-BP

To determine if the sequence binding specificity ofERE-BP were similar to ERa,
EMSA assays were performed by incubating a human breast cancer cytosol with various
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Figure 17. ERE-BP binding to a variety of hormone response element sequences. EMSA
assays were performed by incubating a breast cancer cytosol with various

ePJlabeled
2

sequences. The HRE sequences tested include those forVitA2 , jun, h-fos, pS2, cathepsin
D, prolactin and PR form BEREs, as well as the progesterone response element (PRE),
the glucocorticoid response element (GRE) and two scrambled polynucleotide sequences.
Lane 1 contains the

ePJVitA2-ERE only without extract present in the reaction.
2
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eP]labeled sequences (Figure 17). Those tested include ERE sequences in the VitA2,
2

jun, h-fos, pS2, cathepsin D, prolactin and PR form B genes, as well as the progesterone
response element (PRE), the glucocorticoid response element (GRE) and two scrambled
sequences. Although the ERE-BP appeared to exhibit different affinities for the wide
variety of sequences, the proteins exhibited binding to each sequence tested, including the
scrambled sequences. This suggests that the ERE-BP do not bind specifically to ERE
sequences and thus may be general DNA binding proteins that may not recognize a
specific nucleotide sequence.
To further explore the DNA binding of ERE-BP, competition experiments were
performed with unlabeled response element sequences for the VitA2 and pS2 genes as
well as with unlabeled thyroid hormone response element (TRE) and a mutant VitA2
(VitA2-mut) sequences (Figure 18). The TRE sequence used was a palindrome (TREpal).
Presence of the ERE-BP band after addition of the unlabeled competitor indicates that the
protein does not bind to that sequence as tightly as to

ep]VitA2. Upon addition of 1252

fold molar excess of unlabeled VitA2, pS2 and VitA2-mut sequences, a decrease in the
amount of ERE-BP was observed. However, there was no decrease observed with the
addition of TREpal, indicating that the ERE-BP did not recognize this sequence. When
the same experiment was performed with the rhERa control, a decrease in the amount of
ERa was observed with the addition of unlabelled VitA2, pS2 and TRE, but not with
VitA2-mut sequences. These data indicate that ERE-BP and ERa exhibit distinct DNA
binding specificities.
Several additional sequences were tested by incubating

ep]VitA2-ERE and a
2

breast cancer reference powder cytosolic extract in the presence of 125-fold molar excess
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Figure 18. Competition of VitA2-ERE recognition by ERE-BP using various unlabeled
response element sequences. rhERa (lanes 1-5), a breast carcinoma extract (lanes 6-10)
and an extract of a breast cancer reference specimen (lanes 11-15) were incubated
individually with

C2p]VitA2-ERE

and 125-fold molar excess of unlabeled sequences

VitA2, pS2, TRE and a mutant VitA2 (VitA2-mut), then analyzed by EMSA. Presence of
the ERE-BP band after addition of the unlabeled competitor indicates that the protein
does not bind to that sequence as tightly as to
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Figure 19. Specificity of ERE-BP binding to VitA2-ERE. Competition analyses were
performed using 1 ng of

ep]VitA2-ERE and 15 ug of cytosolic protein from a breast
2

cancer reference specimen that was incubated in the presence of 125-fold molar excess of
unlabeled competitor (various response element sequences indicated). The extent of
competition is expressed as percent of the control, which was measured is in the absence
of an unlabeled polynucleotide sequence.
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of several unlabeled competitor DNA sequences (Figure 19). Results show that the pS2,
PR-isoform B and rat prolactin ERE sequences competed to the greatest extent with
VitA2. The VitA2 and VitA2-mut sequences only inhibited binding by 50-60%. The
TFIID sequence also showed only 50-60% inhibition of binding. The BCL2 ERE,
TREpal and OCT-1 and 2 sequences showed little or no competition in the presence of

ep]VitA2-ERE. OCT-l and 2 are both transcription factors that are members of the
2

POU domain family and bind to sequences unrelated to EREs [197;198]. These results
also suggest that the ERE-BP we are investigating appear to have different affinities for
various sequences, but do not recognize specifically ERE sequences and as such they
appear to be general DNA binding proteins with broad specificity.

Earlier, Gray and Gorski reported that the ERE-BP observed

III

rat uterine

cytosols also were inhibited by VitA2 and mutant VitA2 ERE sequences by 50-60%,
which is similar to our results [187]. In their experiments OCT-l sequences inhibited
binding by approximately 10%. This is similar to data observed in this study with breast
cancer ERE-BP. However, they showed that the TFIID sequence inhibited binding by 8090%, while we only observed 50-60% inhibition of binding by the ERE-BP in breast
cancer cytosol. Chen et al. reported that the ERE-BP they identified in New World
primate cells was inhibited by 100% in the presence of a consensus ERE sequence [182].
In this experiment the TREpal sequence did not inhibit binding, which is similar to our
results from this study.
There are many classes of DNA-binding proteins (e.g., transcription factors,
polymerases, nucleases, DNA repair proteins and histone proteins) beyond those that
recognize ERE sequences specifically. Furthermore, several classes of proteins recognize
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particular elements of DNA structure other than the nucleotide sequence (e.g., single or
double-strand breaks). Novel DNA-binding proteins identified in this work may belong to
one of these classes of proteins and subsequent studies described in Chapter III will
address this.

ERE titrations in the presence of therapeutic estrogens
Both Chen et al. [186] and Gray and Gorski [187] reported that 17~-estradiol
represses ERE-BP binding to the ERE. Chen et al. showed that 1

~M

estradiol restored

the association of ERa with the ERE sequence in MCF-7 cells. They also reported that
tamoxifen was able to mimic this response at a concentration of 10 nM. Gray and Gorski
showed that ERE-BP binding to the ERE decreased in rat uterine cytosols with a single
1.0

~g

dose of estradiol [187]. For these reasons, we performed ERE titrations in the

presence of various estrogens to determine the influence on ERE-binding affinities.
ERE titrations of rhERa and ERE-BP were performed independently in the
presence of ethanol or 1

~M

DES, 4-hydroxytamoxifen,

17~-estradiol

or raloxifene, as

shown in Figure 20. As discussed previously, tamoxifen is a SERM that is recognized by
the ER ligand binding domain and enhances its DNA-binding activity and 4hydroxytamoxifen is the active metabolite of tamoxifen [60;82]. DES is a synthetic
estrogen receptor agonist with extremely high affinity for the ligand binding domain that
also enhances the ERE-binding activity of the estrogen receptor. Addition of DES, 4hydroxytamoxifen,

17~-estradiol

or raloxifene resulted in a significant increase in ERE-

binding by rhERa compared to the ethanol control (Figure 21). The Kd of rhERa binding
to the ERE in the presence of 17~-estradiol was 6.1 X 10- 10 M. This is similar to
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ERE Concentration

B~~
.'

Figure 20. Representative ERE titration of rhERa (A) and ERE-BP (B) in the presence of
1 11M diethylstilbestrol. EMSAs were performed as described in Materials and Methods
with varying amounts of

ep]VitA2-ERE.
2

rhERa was incubated with 1 11M

diethylstilbesterol (DES) for 30 minutes before the addition of 0.2-14 ng ERE. Cytosol (5
I1g total protein) from a breast cancer reference specimen containing ERE-BP was
incubated with 1 11M diethylstilbesterol (DES) for 30 minutes before the addition of 0,537 ng ERE. Gels were scanned and bands quantified using OptiQuant@ software as
described in Materials and Methods.
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Figure 21. Titration of rhERa with increasing concentrations of

ePJVitA2-ERE in the
2

presence of various therapeutic estrogens. Data were modeled using one-site binding
kinetics with GraphPad Prism®. Addition of DES C+), 4-hydroxytamoxifen C.), 17~estradiol C-) or raloxifene COY) resulted in a significant increase in ERE-binding
compared to that of the ethanol control

C.).

experiments are plotted.
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Figure 22. Titration of an ERE-BP preparation from a breast cancer reference specimen
with increasing concentrations of

ep]VitA2-ERE in the presence of various therapeutic
2

estrogens. Data were modeled using one-site binding kinetics with GraphPad Prism®.
Addition of DES (+), 4-hydroxytamoxifen

(.),17~-estradiol

(_) or raloxifene ( .... ) did

not cause a significant increase in ERE-binding compared to that of the ethanol control
( .). Means and SD of results from triplicate experiments are plotted.
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published results of 9.2 X 10- 10 M [199]. In the presence of 1 /lm of either DES, 4hydroxytamoxifen,

17~-estradiol

or raloxifene, the ERE binding capacity of the ERE-BP

was not statistically different compared to that of the ethanol control (p=0.99) (Figure
22). The Kd for ERE-BP binding to the ERE in the control was 2.4 X 10-8 M. In studies
by Gray and Gorski, ERE-BP bound to the ERE with an apparent Kd of 1.2 X 10-9 M
[187]. This is slightly lower than our results. These results suggest that the DNA binding
activity of the ERE-BP is not affected by these estrogenic compounds, indicating a lack
of a sex steroid ligand binding domain.

Correlation of ERE-BP binding activity and estrogen responsive genes

IfERE-BP are binding to the ERE and competing with ERa in vivo, it is expected
that either up-regulation or down-regulation of estrogen responsive genes would occur.
To determine whether ERE-BP binding activities are correlated with expression of
estrogen-responsive genes, ERE-BP levels measured by EMSA in cytosols from 124
primary breast carcinoma specimens were compared to expression levels of 16 genes
containing ERE sequences. Microarray data were obtained from previous studies from
our laboratory in collaboration with Arcturus Applied Genomics. The data were derived
from the use of populations of breast carcinoma cells procured by laser capture
microdissection (LCM) from 247 primary breast cancer specimens [191;200]. Total RNA
was extracted from LCM-procured cells followed by two rounds of amplification and
hybridization to custom microarray chips (Agilent Technologies) containing

~22,000

genes. Cy5/Cy3 ratios were determined using Universal RNA (Stratagene) as a reference.
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Table 1. Representative genes known to contain ERE sequences that were evaluated in
micro array analyses of LCM-procured human breast carcinoma cells.

Gene Symbol

Gene Name

BCL2

B-cell CLL/lymphoma 2

BRCAI

Breast cancer 1, early onset

C3

Complement component 3

CTSD

Cathepsin D

COX7RP

Cytochrome c oxidase subunit VIla-related protein

ESR2

Estrogen receptor beta

TRIM25

Tripartite motif-containing 25/ estrogen responsive finger protein

LTF

Lactoferrin

PGR

Progestrone receptor

TFFI

Trefoil factor l/pS2

CAXIl

Carbonic anhydrase 12

RERG

RAS-like, estrogen-regulated growth inhibitor

CD34

CD34 antigen

EDGI

Endothelial differentiation sphingolipid GPCR 1

NQOI

NAD(P)H dehydrogenase quinone 1

59

A list of human genes reported to contain ERE sequences that were analyzed is
shown in Table 1. Genes containing ERE sequences were selected from published reports
[88;201;202]. Pearson correlations were performed to determine if an association exists
between the expression level of an individual gene and the level of ERE-BP binding
activity; however, no significant correlations were identified (Table 2). The population of
specimens was then divided into two groups, those exhibiting low ERE-BP binding
exhibited activities and those with high ERE-BP binding activities as determined by the
median ERE-BP binding activity. A t-test was then used to determine if there was a
significant difference in the expression levels of each gene between the two groups of
carcinoma specimens. No significant differences were observed between the groups for
any of the genes analyzed (Table 2). These results suggest that the expression ofERE-BP
is not correlated with the transcription of these estrogen responsive genes. This confirms
other results described in this Chapter indicating these unidentified DNA-binding
proteins are not involved ERE-mediated transcription.

Summary and Conclusions

While investigating ERE-binding properties of ERa in de-identified human breast
cancer extracts, proteins with different migration properties that also bind to ERE
sequences were observed. In order to unravel the apparent role of these proteins in breast
cancer, we initiated characterization studies. Recognition properties of ERE-BP were
evaluated by electrophoretic mobility shift (EMSA) with the ERE sequence

ep]VitA2.
2

ERE-BP were present in a variety of tissues types including breast, ovarian, uterine and
colon cancers and normal tissues indicating that the proteins are ubiquitous. These
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Table 2. Correlation of cytosolic ERE-BP levels with candidate genes containing ERE
sequences known to be expressed in breast carcinoma cells.

GENE 10

PEARSON CORRELATION

t TEST P VALUE

PVALUE

ESR1

0.03

0.72

0.43

BCL2

-0.01

0.95

0.98

BRCA1

0.02

0.86

0.21

C3

0.01

0.91

0.59

CTSD

-0.12

0.17

0.16

COX7RP (COX7A2L)

-0.10

0.27

0.47

ESR2

-0.04

0.68

0.16

-0.004

0.97

0.38

LTF

-0.12

0.20

0.20

PGR

-0.07

0.47

0.31

TFF1 (pS2)

-0.01

0.94

0.88

CAXII

0.02

0.79

0.97

RERG

0.08

0.39

0.22

CD34

0.01

0.90

0.97

EDG1

-0.03

0.71

0.87

NQ01

-0.04

0.65

0.42

TRIM25 (ZNF147)
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proteins are present in both the cytoplasm and nucleus although higher activities were
detected in the nuclear extracts. Our results indicate that ERE-BP did not supershift with
several anti-ERa or

ER~

antibodies recognizing different ER epitopes suggesting that

they are not fragments of ERa or

ER~.

Additionally, ERE-BP did not supershift with

antibodies to the known ERE-binding proteins ERRa, COUP-TFl, hnRNP ClIC2,
hnRNP D or the related hnRNP D-like. However, we demonstrated that the ERE-BP
compete with rhERa for binding to the VitA2-ERE yet the ERE-BP exhibited
significantly different sequence specificity compared to that of human ERa. Collectively,
our results indicate that the ERE-BP we observed in breast cancer extracts are not
specific for the ERE sequences and appear to be general DNA-binding proteins. To
further support this conclusion, various estrogens had no effect on the ERE-binding of
these proteins in contrast to rhERa. Furthermore, the ERE-BP activity levels did not
correlate with levels of estrogen responsive genes indicating that ERE-BP do not appear
to be involved directly in ERa- or ERE-mediated transcription. The investigations in the
next chapter will focus on purification and identification of the ERE-BP we have
detected.
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CHAPTER III
PURIFICATION AND IDENTIFICATION OF DNA-BINDING PROTEINS
USING IMMUNO-BASED METHODS AND MASS SPECTROMETRY

Introduction

The purpose of this investigation was to purify and identify the candidate ERE-BP
discovered in breast cancer biopsies. Results from Chapter II indicated that ERE-BP were
present in a variety of tissues types including breast, ovarian, uterine and colon cancers
indicating that the protein is ubiquitous. These proteins were also present in both the
cytoplasm and nucleus although it was observed to be present at higher concentrations in
the nucleus. These proteins do not share sequence homology with either estrogen receptor
isoform a or

~,

or to the known ERE-binding proteins ERRa, COUP-TFl, hnRNP

CI/C2, hnRNP D or the related hnRNP D-like. Although the ERE-BP competed with

rhERa for binding to the VitA2-ERE, these proteins exhibited significantly different
sequence specificity compared to that of human ERa. Our results suggested that the
observed ERE-BP do not specifically recognize the ERE and appear to be DNA-binding
proteins with broad specificity.
To further support our hypothesis, the presence of various estrogens had little
effect on the ERE-binding of these proteins in contrast to the properties of rhERa.
Furthermore, the ERE-BP activity levels in breast carcinomas did not correlate with
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levels of estrogen responsive genes indicating that ERE-BP in breast carcmoma
preparations are not influencing ERa-mediated transcription. The investigations of this
chapter focus on purification and identification of the observed ERE-BP using immunobased methods and mass spectrometry. Additional immuno-based methods such as
western blots and supershift assays were used for confirmation of the mass spectrometry
results.

Methods and Materials
Preparation of nuclear extracts

Reference powders of human breast and uterine carcinomas were homogenized using a
Polytron PT 10-35 in 10 mM HEPES buffer, pH 7.9 containing 10 mM KCI, 0.1 mM
EDTA, 1 mM DTT, 0.5 mM PMSF, and 0.01

~g/~l

aprotinin, leupeptin and pepstatin A.

Lysates were centrifuged at 4°C at 15,000 x g for 10 minutes. The nuclear pellet was
resuspended in 20 mM HEPES buffer, pH 7.9 containing 0.4 M NaCI, 1 mM EDTA, 10%
glycerol, 1 mM DTT, 0.5 mM PMSF, and 0.01

~g/~l

aprotinin, leupeptin and pepstatin

A. The resuspended pellets were mixed at 4°C for 2 hours and centrifuged 4°C, 15,000 x
g for 10 minutes. Nuclear extracts were concentrated and desalted with Amicon Ultra
YM-1O columns (Millipore). To enrich the extracts for ERE-BP, the twelve most
abundant plasma proteins were depleted using a Seppro™ MIXED12 Kit (GenWay
Biotech) according to the manufacturer's protocol [203].
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Purification ofERE-BP

Depleted nuclear extracts (800 Jlg of total protein) were incubated overnight at 4°C with
300 pmol of either a biotinylated or unlabeled ERE sequence in 20 mM HEPES buffer,
pH 7.9 containing 800 ng of poly (dI-dC) (Amersham), 10 mM KCI and 1% glycerol.
Sequences used are shown in Table 8 (See Appendix). Candidate ERE-BPIERE
complexes were then incubated with 300 JlI of NeutrAvidin agarose beads (Pierce) for 4
hours at 4°C with constant rotation. These beads were chosen over streptavidin beads
because they exhibit lower non-specific binding. Beads were washed three times in 20
mM HEPES pH 7.9 containing 10 mM KCI and 1% glycerol and three times in 20 mM
HEPES buffer, pH 7.9 containing 0.2 M KCl. Bound proteins were eluted in 20 mM
HEPES buffer, pH 7.9 containing 1.0 M KCl. Elution and wash fractions were desalted
and concentrated with Amicon Ultra YM-I0 columns (Millipore). Four separate
experiments were performed using the same protocol and fractions were pooled to insure
sufficient total protein for detection by mass spectrometery. A flow diagram showing the
method of purification is shown in Figure 23.

Mass spectrometry

Fractions containing the candidate proteins eluted from the imunobeads were analyzed by
tandem liquid chromatography and mass spectrometry (2D-LC-MSIMS) [204]. Spectra
were obtained with an LTQ ion trap mass spectrometer (Thermo Fisher Scientific).
Scaffold software (version Scaffold_3_00_08, Proteome Software) was used to analyze
the results from 2D-LC-MS/MS for protein identifications. Protein identifications were
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Experimental

Prepare .....clear extracts

Control

1
Incmate ooclear extracts with
blo~-ERE or control ERE
overn~t, 4 0 C

-1

1

Incmate with NeutrAvldln beads

for4 hr,4"C

1

1
Non-specific binding

1-

Flowthro~

Wash beads with 0.2 M KCI

1-
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Elute with 1.0 M KCI

1
1

Desalt & Concentrate

]I Biotin

NeutrAvidin Bead

Analyze by EMSA & MSNS

Figure 23. Method for purification of candidate ERE-BP. Nuclear extracts were
concentrated and desalted with Amicon Ultra YM-IO columns. The twelve most
abundant plasma proteins were depleted using a Seppro™ MIXED12 Kit (GenWay
Biotech). Depleted nuclear extracts (800 Ilg of total protein) were incubated overnight at
4°C with either 300 pmol of a biotinylated or unlabeled ERE sequence in 20 mM HEPES
buffer pH 7.9 containing 800 ng of poly (dI-dC) (Amersham), 10 mM KCI and 1%
glycerol. Candidate ERE-BPIERE complexes were then incubated with 300 III of
NeutrAvidin agarose beads (Pierce) for 4 hours at 4°C with constant rotation. Beads were
washed three times in 20 mM HEPES buffer, pH 7.9 containing 10 mM KCl and 1%
glycerol and three times in 20 mM HEPES buffer, pH 7.9 containing 0.2 M KCl. Bound
proteins were eluted in 20 mM HEPES pH 7.9 containing 1.0 M KCl. Elution and wash
fractions were desalted and concentrated with Amicon Ultra YM-IO columns (Millipore).
All fractions were analyzed by EMSA and elutions were analyzed by mass spectrometry.
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accepted at a probability of greater than 99.9% that contained at least two identified
peptides. Peptide identifications were accepted at a probability of greater than 95.0%.

UV crosslinking

Reactions with protein extracts and

ep]VitA2-ERE were prepared as described above
2

for EMSAs and UV crosslinked on ice at 1500 J/cm 2 for 30 minutes. Samples were
separated on an 8% SDS-PAGE gel, dried, exposed to phosphor screens overnight and
analyzed with OptiQuant@ software. Migration of each

eP]ERE-protein complex band
2

was measured with OptiQuant@ software and molecular weights of detected bands were
extrapolated using protein molecular weight standards (EZ-RunTM Pre-Stained Rec
Protein Ladder, ThermoFisher).

Western blot analysis

Proteins were separated by 10% SDS-PAGE and transferred to a nitrocellulose
membrane (Bio-Rad). Membranes were blocked with 5% nonfat dry milk overnight. The
primary antibodies utilized in these experiments were Ku70 (D35, polyclonal, Cell
Signaling), Ku70 (Ab-4, monoclonal, Thermo Fisher Scientific), Ku80 (Ab-2,
monoclonal, Thermo Fisher Scientific), Ku80 (C48E7, monoclonal, Cell Signaling) and
~-actin

(polyclonal, Cell Signaling). All primary antibodies were used at a 1:2000

dilution. The secondary antibodies used were HRP-goat anti-rabbit and HRP-goat antimouse (ZymediLife Technologies). Secondary antibodies were used at a dilution of
1:5000. Blots were visualized with Immobilon Western Chemiluminescent HRP substrate
(Millipore) using the protocols supplied by the manufacturer.
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Supershijt assay

Protein extracts were incubated with 50 ng non-specific DNA, poly (dI-dC) (Amersham),
10 mM KCI, 1% glycerol and

eP]labeled ERE sequences in 40 mM Tris-HCI buffer, pH
2

8.0, containing 500 JlM PMSF and 10 JlM monothioglycerol overnight at 4°C. Antibodies
were added to the reaction and incubated for 30 minutes before addition of

ep]ERE. The
2

antibodies used included hnRNP D (polyclonal, GenWay Biotech), hnRNP D (T-IO,
polyclonal, Santa Cruz), hnRNP DL (polyclonal, GenWay Biotech), hnRNP ClIC2 (4F4,
monoclonal, Santa Cruz), ERRa (monoclonal, R&D Systems), COUP-TFI (monoclonal,
R&D Systems), Ku70/Ku80 (3F247, monoclonal Santa Cruz), Ku70/80 (Ab-3,
monoclonal, Thermo Fisher Scientific), Ku80 (Ab-2, monoclonal, Thermo Fisher
Scientific), Ku80 (C48E7, monoclonal, Cell Signaling), phospho-ATM (D6H9,
monoclonal, Cell Signaling), phospho-BRCAI (Ser 1524, polyclonal, Cell Signaling),
DNA-PK (polyclonal, Cell Signaling), Mrell (31H4, monoclonal, Cell Signaling),
phospho-p95lNBS 1 (Ser343, polyclonal, Cell Signaling), Rad50 (polyclonal, Cell
Signaling), Rad52 (polyclonal, Cell Signaling), XLF (polyclonal, Cell Signaling). Normal
mouse and rabbit IgG (Santa Cruz) were used as controls.
Reactions were separated by 5% polyacrylamide gel electrophoresis. The gel was
pre-run for 30 minutes at 150 V at 4°C in 0.5x TBE buffer (1 M Tris-HCI, pH 8.6,
containing 831 mM boric acid, 10 mM EDT A). Samples were then loaded, followed by
electrophoresis at 300 V for 5 minutes, and then 180 V for 4 hours. Subsequently, gels
were dried and exposed to phosphor screens (Perkin Elmer) overnight. The bands
recognizing

eP]ERE-protein
2

complexes and free
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ep]ERE
2

were visualized and

quantified using a Cyclone Storage Phosphor System™ with OptiQuant® software
(Perkin Elmer) as described in Chapter II.

Results and Discussion

Removal of high abundant proteins from nuclear extracts

To determine the identity of the ERE-BP present in breast cancer extracts, a
method of purification was established. In order to enrich the extracts for candidate EREBP, the twelve most abundant plasma proteins were depleted from the samples. These
include serum albumin, IgG, fibrinogen, transferring, IgA, IgM, HDL, haptoglobin, aIantitrypsin, aI-acid glycoprotein and a2-macroglobulin. Removing these proteins has
been shown to increase yield for protein detection assays [203;205]. Nuclear extracts
made from a uterine cancer reference powder (NE) and a separate preparation of the same
NE that was depleted of the high abundant proteins (NE-HAP) as described in Materials
and Methods were analyzed by EMSA, which showed that the ERE-BP were present in a
higher concentration in the plasma protein depleted samples (Figure 24A). The untreated
NE, the NE depleted of high abundant proteins (NE-HAP) and the fractions eluted from
the immunobead that contained the high abundant proteins (HAP) were analyzed by 10%
SDS-PAGE. The proteins on the gel were stained with SYPRO™ Ruby protein stain
(Figure 24B). Results demonstrate that the majority of the high abundant proteins were
removed from the nuclear extract and there was enrichment for the ERE-BP in the
resulting preparation.
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Figure 24. Removal of high abundant proteins from nuclear extracts of a uterine cancer
reference powder. (A) A representative nuclear extract made from a uterine cancer
reference powder (NE) and a separate preparation of the same NE that was depleted of
the high abundant proteins (NE-HAP) as described in Materials and Methods were
analyzed by EMSA. Equal amounts of protein were added in each lane. (B) The untreated
NE, the NE depleted of high abundant proteins (NE-HAP) and the fractions eluted from
the immunobead that contained the high abundant proteins (HAP) were analyzed by 10%
SDS-PAGE. The proteins on the gel were stained with SYPRO™ Ruby protein stain and
EZ-Run™ pre-stained Rec protein ladder (Thermo-Fisher) was used as molecular weight
markers.
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Influence of various biotinylated DNA sequences on the "pull-down" of candidate EREBP from nuclear extracts

To determine the optimal DNA sequences that could be used for purification of
ERE-BP and which could be used as negative controls, candidate ERE-BP were purified
from nuclear extracts using NeutrA vi din beads and various biotinylated DNA sequences.
VitA2, a hairpin VitA2, pS2 and PR form b ERE sequences were tested. After the pulldown reaction, the proteins eluted from these sequences were analyzed by EMSA (Figure
3). Each of these sequences was able to pull-down ERE-BP from nuclear extracts. Our
previous results showed that a palindromic TRE sequence showed the least amount of
competition in the presence of VitA2-ERE (Figure 19, Chapter II), therefore both a
palindromic and direct repeat TRE oligonucleotide were tested as negative controls.
EMSA analysis shows that both of these sequences were also able to pull down ERE-BP
from nuclear extracts, therefore are unsuitable as negative controls (Figure 25). Using
EMSA we previously illustrated that the ERE-BP also bound to multiple DNA
oligonucleotides that did not contain ERE sequences (Figure 17, Chapter II). The results
shown in Figure 25 confirm our previous data suggesting the ERE-BP may be general
DNA-binding proteins and are not specifically recognizing the ERE sequences.

Purification of ERE-BP for analysis by mass spectrometry

In order to determine the identity of these proteins by mass spectrometry,
candidate ERE-BP were purified from nuclear extracts prepared from a uterine cancer
reference powder using the VitA2-ERE as described above. A uterine cancer reference
powder was chosen over breast in order to ensure the highest concentration ofERE-BP
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TR E
TR E VitA2
pal VitA2 DR HP

Figure 25. Influence of various biotinylated DNA sequences on the "pull-down" of
candidate ERE-BP from nuclear extracts. ERE-BP were purified from nuclear extracts
using NeutrA vidin beads and biotinylated DNA sequences as described in Materials and
Methods. Sequences were evaluated for ERE-BP recognition and analyzed by EMSA to
determine which may be useful for purification. VitA2, a hairpin VitA2 (VitA2 HP), pS2,
PR form b (PR) ERE sequences were tested, as well as both a palindromic (TREpal) and
direct repeat TRE (TRE DR) sequence. A nuclear extract prepared from a uterine cancer
reference specimen is shown as a control (NE).
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possible in the starting material, as illustrated by comparing EMSA profiles from
different extracts. High abundant proteins were depleted from these nuclear extracts
which were then incubated with either a biotinylated or unlabeled VitA2-ERE, followed
by incubation with NeutrAvidin agarose beads. Without DNA biotinylation, the
NeutrAvidin agarose beads do not exhibit specific binding to the protein-DNA complex,
allowing only proteins non-specifically bound to the beads to be pulled down. Therefore,
unbiotinylated VitA2-ERE was used as a negative control. Fractions from each
purification step were analyzed by EMSA and results are shown in Figure 26A.
Nuclear extracts exhibiting the presence of ERE-BP in the starting material is
shown in Lane 1. Lane 2 showed the increased amounts of ERE-BP in nuclear extracts
after removal of the high abundant proteins. These results confirm previous results that
removal of the high abundant proteins enriches for the ERE-BP. Proteins which were not
bound to the ERE-NeutrAvidin bead complex (flow-through) are shown in Lanes 3
(control) and 4 (biotinylated VitA2). The fractions resulting from the wash steps are
shown in Lanes 5 (control) and 6 (biotinylated VitA2). Proteins that were eluted from the
ERE-NeutrAvidin bead complex are shown in Lanes 7 (control) and 8 (biotinylated
VitA2). ERE-BP were eluted from the biotinylated VitA2-ERE but not the control
unlabeled ERE. The control and experimental elution fractions were separated by SDSPAGE electrophoresis and the gels were stained with SYPRO™ Ruby protein stain to
determine the number and relative amount of protein bands present (Figure 26B). The
control elution did not contain as many proteins as the labeled VitA2 elution and there
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Figure 26. Purification ofERE-BP for analysis by mass spectrometry. (A) Fractions from
each step of the purification process were analyzed by EMSA. Nuclear extract from a
uterine cancer reference powder showing the presence of ERE-BP in the starting material
is shown in Lane 1. Lane 2 shows the increased amounts of ERE-BP in nuclear extracts
after removal of the high abundant proteins. Proteins which were not bound to the ERENeutrAvidin bead complex (flow-through) are shown in Lanes 3 (control) and 4 (VitA2ERE). The fractions resulting from the wash steps are shown in Lanes 5 (control) and 6
(VitA2-ERE). Proteins identified as ERE-BP that were eluted from the ERE-NeutrAvidin
bead complex are shown in Lanes 7 (control) and 8 (VitA2-ERE). (B) A SYPRO™ Ruby
protein stain was reacted with proteins in the control and experimental elutions to
determine the number and amount of proteins present.
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appeared to be a sufficient amount of the purified proteins to be analyzed by mass
spectrometry.

Identification of candidate ERE-BP by mass spectrometry

Proteins eluted from the control VitA2-ERE and the biotinylated VitA2, the
hairpin VitA2 and the BCL2 ERE were analyzed by mass spectrometry in three separate
experiments as described in Methods and Materials. Table 3 shows a list of the proteins
identified. Scaffold software was used to analyze the protein identifications and the
spectral count for each protein is shown. The spectral count is the count given to an
identified peptide spectra. Scaffold normalizes these counts across samples by taking the
average and then multiplying by the average divided by the individual sample's sum.
Although twenty seven proteins were identified using this approach [204], only 8
were identified that were present in at least one labeled ERE elution and not the control:
pyruvate kinase isozymes MI/M2 isoform M2 (PKM2), X-ray repair crosscomplementing protein 5 (XRCC5/Ku80), X-ray repair cross-complementing protein 6
(XRCC6/Ku70), heterogeneous nuclear ribonucleoprotein D-like (HNRPDL), a-actinin 4

(ACTN4), high mobility group protein Bl (HMGBl), periostin isoform 1 (POSTN) and
protein disulfide isomerase A3 (PDIA3).
PKM2 is a pyruvate kinase that catalyzes the transfer of a phosphoryl group from
phosphoenolpyruvate to ADP during glycolysis, generating ATP and pyruvate [206].
PKM2 also interacts with the DNA-binding domain of the transcription factor Oct-4 to
regulate transcription [207]. Ku70 and Ku80 form a heterodimer and make up the DNAbinding subunits of DNA-dependent protein kinase (DNA-PK), which is involved DNA
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Table 3. List of proteins in the final purified sample that were identified by mass
spectrometry.
Identified Proteins

MW
(kDa)
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Identified Proteins
~rythroid
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~I
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Proteins eluted from the control VitA2-ERE sequence and the biotinylated VitA2, the
hairpin VitA2 and BeL2 ERE were analyzed by mass spectrometry in three different
experiments as described in Methods and Materials. Sequences of the various EREs are
described in the Appendix. Scaffold software was used to analyze the protein
identifications and the spectral count for each protein is shown. The spectral count is the
count given to an identified peptide spectra. Scaffold nonnalizes these counts across
samples by averaging them and then multiplying by the average divided by the individual
sample's sum.
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double strand break repair via non-homologous end-joining [114]. Polymorphisms in
these genes are associated with increased breast cancer susceptibility [208-210].
HNRPDL belongs to the subfamily of heterogeneous nuclear ribonucleoproteins and is an
RNA and DNA binding protein involved in pre-mRNA processing [211]. ACTN4 is an
actin filament cytoskeletal protein that has recently been shown to be involved in tumor
development and progression [212]. ACTN4 has also recently been shown to be a nuclear
receptor coactivator that regulates ERa-mediated transcription in breast cancer cells
[213]. In addition, HMGBI is a ubiquitous nuclear DNA-binding protein that induces
structural changes in the DNA to facilitate in transcription [214;215] while POSTN is an
extra-cellular matrix protein that plays a role in bone, tooth and cardiac development
[216;217]. Increased levels of this protein are associated with breast cancer [217],
however there is currently no evidence that periostin functions as a DNA-binding protein.
PDIA3 is a member of the family of protein disulfide isomerases which catalyze
formation, reduction and isomerization of disulfide bonds in proteins in the endoplasmic
reticulum [218]. PDIA3 has also been shown to bind DNA in the nucleus and is
associated with the nuclear matrix [219].
Since most of these candidate proteins have DNA-binding activity, further
analysis was necessary to confirm which of these were components of the ERE-BP/ERE
complex. Of these eight proteins that were not present in the control elutions, only three
appeared in ERE elutions in more than one of the mass spectrometry experiments: Ku70,
Ku80, and a-actinin, making these proteins the most likely potential candidates. The
molecular weights of Ku70, Ku80, and a-actinin are 70, 83 and 105 kilodaltons (kDa),
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respectively. Determination of the molecular weight of the ERE-BP will further narrow
down which protein candidate to pursue.

Determination of molecular weight of ERE-BP
To determine the molecular weight of the ERE-BP and narrow down the potential
protein candidates, UV crosslinking experiments were performed. Nuclear extracts from
breast and uterine cancer reference powders as well as proteins eluted from the pS2-ERE
described above were UV crosslinked to VitA2-ERE and separated by SDS-PAGE
(Figure 27). Nuclear extracts contained three complexes at approximately 47, 74 and 82
kDa (Figure 27A). The 74 kDa band was present at significantly higher concentrations
compared to the 47 kDa and 82 kDa bands. These molecular weights correlate with the
weights of Ku70 and Ku80, but not with a-actinin. The 47 kDa band correlates with the
molecular weight of hnRNP D-like. The ERE-BP/ERE complex eluted from the
NeutrA vi din beads contained a major protein complex at approximately 72 kDa (Figure
27B). This molecular weight appears to correlate with the weight of Ku70 (XRCC6).
Based on these results and the fact that Ku70 and Ku80 form heterodimers during DNAbinding, we concluded that these proteins were the most likely candidates for the identity
of the ERE-BP.

Western blot analyses of proteins eluted during the purification of ERE-BP with
NeutrAvidin beads
The presence of Ku70 and Ku80 in the fractions collected during purification of
ERE-BP was ascertained by Western blot analyses using antibodies to Ku70 (D35, Cell
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Figure 27. Determination of molecular weight of ERE-BP in reference specimens of
human breast and uterine carcinomas. UV crosslinking was performed to determine the
molecular weight of the ERE-BP as described in Materials and Methods. Nuclear extracts
were subjected to UV light to promote crosslinking to VitA2-ERE sequences and
separated by SDS-PAGE (A). Proteins eluted from a pS2-ERE sequence were also
subjected to UV crosslinking to VitA2-ERE sequences and separated by SDS-PAGE (B).
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Figure 28. Western blot analyses of proteins eluted during the purification of ERE-BP
with NeutrAvidin beads. The presence of Ku70 and Ku80 in the fractions collected
during purification of ERE-BP were ascertained by Western blot analyses using
antibodies to Ku70 (D35, Cell Signaling) and Ku80 (C48E7, Cell Signaling). Flowthrough (FT), wash and elution fractions from both a control purification (C) and a
purification using biotinylated VitA2-ERE (V) are shown. A NE from a uterine cancer
reference powder with the high abundant proteins (NE-HAP) removed is also shown.
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Signaling) and Ku80 (C48E7, Cell Signaling) (Figure 28). Flow-through (FT), wash and
elution fractions from both a control purification (C) and a purification using biotinylated
VitA2-ERE (V) are shown. A NE from a uterine cancer reference powder with the high
abundant proteins (NE-HAP) is also shown. Both Ku70 and Ku80 were present in the
control nuclear extract and in the flow-through fractions, but not in the wash fractions.
Both proteins are present in the labeled ERE elution but not from the control elution.
These results confirm those from the mass spectrometry experiments that show Ku70 and
Ku80 were present in the fractions eluted from the immunobeads and support further that
these proteins are the most likely candidates for the identification ofERE-BP.

Recognition of ERE-BP by an antibody detecting heterodimers of Ku70lKu80

To test the hypothesis that Ku70 and Ku80 are present in the ERE-BP/ERE
complex, supershift assays were performed on nuclear extracts of reference powders,
nuclear extracts from which the high abundant proteins were removed and rhERa with an
antibody that recognizes the Ku70/80 heterodimer. A supershift of the ERE-BP was
observed with an antibody to Ku70/80 in both of the nuclear extract samples but not with
the control mouse IgG (Figure 29A). No supershift of rhERa was observed with this
antibody or with the control IgG.
These results indicate that this Ku70/80 antibody specifically recognizes and
binds to the ERE-BP. To further validate that the observed ERE-BP are a Ku70/80
heterodimer, supershift assays were performed with additional antibodies against the
Ku70/80 heterodimer or Ku70 and Ku80 individually (Figure 29B). Nuclear extracts
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Figure 29. Recognition ofERE-BP by an antibody detecting heterodimers of Ku70/Ku80.
(A) Supershift assays were performed on uterine cancer reference powder nuclear
extracts, uterine cancer reference powder nuclear extracts (Lanes 1 and 2) after removal
of high abundant proteins (Lanes 3 and 4) and rhERa (Lanes 5 and 6) with an antibody
that recognizes the Ku70/80 heterodimer (Lanes 2, 4, 6) (Santa Cruz). Normal mouse IgG
was used as a negative control (Lanes 1, 3, 5). (B) Uterine cancer reference powder
nuclear extracts were incubated with either normal mouse IgG (Lane 2), normal rabbit
IgG (Lane 3), antibody to Ku70/80 (Santa Cruz) (Lane 4), antibody to Ku70/80 (Ab-3,
Thermo Fisher) (Lane 5), antibody to Ku80 (ab-2, Thermo Fisher) (Lane 6) or antibody
to Ku80 (C48E7, Cell Signaling) (Lane 7). (C) Untreated nuclear extracts (NE) were
separated by EMSA (Lane 1) and compared with the EMSA profile of a nuclear extract
that was treated with either an antibody recognizing heterodimers of Ku70/80 (Santa
Cruz) (Lane 3) or with a control normal mouse IgG (Lane 2) followed by incubation with
Protein AlG agarose beads (Santa Cruz).
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from a uterine cancer reference powder nuclear extracts were incubated with either
normal mouse IgG, normal rabbit IgG, an antibody to Ku70/80 (Santa Cruz), an antibody
to Ku70/80 (Ab-3, Thermo Fisher), an antibody to Ku80 (ab-2, Thermo Fisher) or with
an antibody to Ku80 (C48E7, Cell Signaling). A supershift of the ERE-BP was observed
with each of these antibodies to Ku70/80 but not with the control mouse or rabbit IgG.
Immunodepletion experiments were also performed to determine whether Ku70/80
antibody recognizes ERE-BP. Nuclear extracts (NE) were incubated with either a control
normal mouse IgG or with an antibody that recognizes the heterodimers of Ku70/80
(Santa Cruz) followed by incubation with Protein A/G agarose beads (Santa Cruz).
Nuclear extracts and immunodepleted samples were analyzed by EMSA (Figure 29C).
ERE-BP were depleted in the samples incubated with a Ku70/80 antibody but not with
the control IgG, supporting the hypothesis that the ERE-BP is a heterodimer of
Ku70/Ku80.

Influence ofantibodies to double strand breaks repair proteins

In order to verify that the ERE-BP are not related to other DNA repair proteins,
supershift assays were performed with antibodies to various double strand break repair
proteins including Ku70 and Ku80 separately (Figure 30). The antibodies used were
Ku80 (C48E7), Ku70 (D35), DNA-PK, phosphor-ATM, Mrell, NBSI, Rad50, Rad52,
XLF and phospho-BRCAI. Normal rabbit IgG was used as a negative control. In both
breast cancer cytosols (Figure 30A) and nuclear extracts (Figure 30B) only the antibody
to Ku80 (C48E7) showed a supershift. Although the Ku70 antibody did not cause a
supershift, these results suggest that the observed ERE-BP are a Ku70/80 heterodimer
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Figure 30. Influence of antibodies to double strand breaks repair proteins on candidate
ERE-binding proteins. Cytosols (A) and nuclear extracts (B) from a representative
reference powder of breast carcinoma were incubated independently with antibodies to
various double strand breaks repair proteins and analyzed by supershift assays. Lane I :
normal rabbit IgG, Lane 2: Ku80 (C48E7), Lane 3: Ku70 (D35), Lane 4: DNA-PK, Lane
5: phosphor-ATM, Lane 6: Mrell , Lane 7: NBSl , Lane 8: Rad50, Lane 9: Rad52, Lane
10: XLF and Lane 11 : phospho-BRCAI. Note that both cytosol and nuclear extracts
contained Ku80.
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and are not related to other double strand break repair proteins. A possible explanation
for the Ku70 antibody not causing a supershift is that the epitope is not accessible under
the non-denaturing conditions of the EMSA and is buried in the tertiary structure of the
protein. For example, the Ku70 antibody used in these experiments recognizes the Nterminus of the protein which forms a f3-barrel structure and is involved in KuSO
dimerization and DNA-binding [145;220]. The KuSO antibody used in these experiments
recognizes the C-terminus of the protein, which is flexible and known to be involved in
protein-protein interactions but not DNA-binding [145;150].

Influence of various antibodies to Ku70lKu80 on ERE-BP in frozen cytosols from breast
cancer

The previous supershift assays were performed on freshly prepared extracts from
various human tissue reference specimens. In order to confirm these results in breast
cancer, supershift assays with various Ku70/S0 antibodies were performed on previously
frozen and stored breast cancer cytosols prepared for the clinical measurement of ER and
PR [20] (Figure 31). Two breast cancer cytosols were analyzed, one showing only the
lower band and one with both bands. Extracts were incubated with either normal mouse
IgG, normal rabbit IgG, an antibody to Ku70/S0 (Santa Cruz), an antibody to Ku70/S0
(Ab-3, Thermo Fisher), an antibody to KuSO (ab-2, Thermo Fisher) or an antibody to
KuSO (C4SE7, Cell Signaling). For the sample containing the lower band only, a
supershift was observed with each antibody to the Ku70/S0 heterodimer and to KuSO
alone, but not with the control mouse or rabbit IgG or the KuSO antibodies alone. These
results suggest that the KuSO antibody doesn't recognize the lower band. It is unlikely
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Figure 31. Influence of various antibodies to Ku70/Ku80 on ERE-BP in frozen cytosols
from breast cancer. Supershift assays of frozen breast cancer cytosols with various
Ku70/80 antibodies were performed. Two breast cancer cytosols were analyzed, one
showing only the lower band (Lanes 1-7) and one with both bands (Lanes 8-14). Extracts
were incubated as described in Materials and Methods with either normal mouse IgG
(Lanes 2, 9), normal rabbit IgG (Lanes 3, 10), antibodies to Ku70/80 (Santa Cruz) (Lanes
4, 11), antibodies to Ku70/80 (Ab-3, Thermo Fisher) (Lanes 5, 12), Ku80 (ab-2, Thermo
Fisher) (Lanes 6, 13) or antibodies to Ku80 (C48E7, Cell Signaling) (Lanes 7, 14) and
separated by supershift assays.
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that this is due to the lower band being Ku70 alone because heterodimer formation is
necessary for DNA binding in EMSA [221;222]. The C-terminal regions of both proteins
and the N-terminal region of Ku70 are required for DNA end binding [220;222].
Heterodimer formation is required for DNA-binding of N-terminal region of Ku70;
however the DNA-binding activity of the C-terminal is independent of heterodimer
formation [220]. A possible explanation is that the heterodimer contains a 69-kDa Ku80
variant rather than the full length protein. This variant has a truncated C-terminal domain
but retains the ability to form a heterodimer with Ku70 and bind DNA [223-226]. Both
Ku80 antibodies used in these experiments recognize the C-terminal domain of the
protein. In contrast, for the sample containing both bands, a supershift was observed with
each antibody to the Ku70/80 heterodimer and the Ku80 antibodies but not with the
control mouse or rabbit IgG. Both bands of the ERE-BP complex observed in breast
cancer cytosols are recognized by a Ku70IKu80 antibody consistent with our previous
results.

Comparison ofKu protein levels and DNA-binding activities measured by EMSA

To determine if the levels of DNA-binding observed in previously frozen breast
cancer cytosols correspond with Ku70 and Ku80 protein levels, 50 samples were
analyzed concurrently by EMSA and Western blot. Cytosols were analyzed by EMSA
using VitA2-ERE as described previously. Western blot analyses were performed using
primary antibodies for Ku70 (Ab-4, Thermo Fisher Scientific), Ku80 (Ab-2, Thermo
Fisher Scientific) and l3-actin (Cell Signaling). Representative EMSA and Western blot
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Figure 32. Comparison of Ku DNA-binding activities and protein levels. To determine if
the levels of DNA-binding observed in previously frozen breast cancer cytosols
correspond with Ku70 and Ku80 protein levels, breast cancer cytosols were analyzed
concurrently by EMSA (A) and Western blot (B). Cytosols were analyzed by EMSA
using VitA2-ERE as described previously. rhERa was used as a control. Western blot
analyses were performed using primary antibodies for Ku70 (Ab-4, Thermo Fisher
Scientific), Ku80 (Ab-2, Thermo Fisher Scientific) and l3-actin (Cell Signaling). Lane 2
contains a nuclear extract prepared from a uterine cancer reference specimen. Lanes 3-9
contain cytosols prepared from breast cancer biopsies.
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results are shown in Figure 32. Samples with various DNA-binding activities were
analyzed by EMSA and compared to Ku70 and Ku80 protein levels. Ku70 protein levels
appear to correlate with EMSA results more consistently than Ku80 protein levels. To
quantify the bands obtained from Western blot analysis, all samples were normalized to
the

~-actin

loading control and then a nuclear extract standard. ImageJ software (NIH)

was used to calculate the relative densities for each band. Ku70 and Ku80 protein levels
were compared to EMSA activities by two-tailed Spearman correlations (Figure 33). A
significant correlation was observed between DNA-binding activities and both Ku70
(r=0.67, p<O.OOOI) and Ku80 (F0.47, p=0.0003) protein levels, the correlation with
Ku80 is not as strong. This is most likely due to the presence of the variant 69-kDa form
of Ku80 which would not be recognized by the antibody used for Western blotting.
Because the DNA-binding activity is a measurement of both Ku70 and Ku80, the levels
of these proteins measured by Western blot were added together and correlated with the
EMSA data, which showed a higher r value than either protein alone (r=0.73, p<O.OOOI).
The protein levels of Ku70 and Ku80 also correlate with each other (FO.58, p<O.OOOl),
which is consistent with the crystal structure of the Ku heterodimer showing that Ku70
and Ku80 bind to DNA in a 1: 1 ratio [145].

Summary & Conclusions

The goals of this investigation were to purify and identify the candidate ERE-BP
from tisssue extracts. A method for purifying and identifying proteins present in tissue
extracts that bind to the ERE was established. This method used a combination of biotin
labeled ERE sequences, NeutrAvidin beads and mass spectrometry. These techniques
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Figure 33. Correlation of Ku DNA-binding activities and protein levels. A two-tailed
Spearman correlation was used to detennine if Ku DNA-binding activities measured by
EMSA are related to Ku70 and Ku80 protein levels measured by Western blot. Ku70
alone (A), Ku80 alone (B), the addition of Ku70 and Ku80 DNA-binding activities (C)
and Ku70 protein levels versus Ku80 protein levels (D) are shown.
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generated a list of candidate proteins that could be tested by antibody-based methods. UV
crosslinking experiments were performed to determine the molecular weight of these
proteins. Based on these data, Ku70 and Ku80 were determined to be the most likely
candidates. Western blot and supershift assays confirmed the presence of these proteins
in breast and uterine cancers. Supershift assays also confirmed that ERE-BP/ERE
complex observed by EMSA was specifically recognized by antibodies to the Ku70/Ku80
heterodimer.
These results are consistent with the data in Chapter II that suggest these proteins
are non-specific DNA-binding proteins that are present in both the cytoplasm and the
nucleus. After the initiation of DSBs, Ku70 and Ku80 form a heterodimer that bind to the
free ends of DNA independent of sequence and structure [118;227-230]. The Ku
heterodimer forms a ring around the DNA but does not make contact with the bases
themselves [145]. Instead, Ku fits sterically to the minor and major groove [145].
Fluorescence anisotropy studies revealed that electrostatic interactions playa large role in
DNA-binding and are possibly the primary mechanism for DNA recognition [231]. Ku70
and Ku80 localize in both the cytoplasm and nucleus [143;154;232-234]. It has also been
shown that Ku70 and Ku80 localize to the nucleus in response to cell cycle status. Ku70
and Ku80 are localized in the cytoplasm and nucleus during late telophase and early G 1,
but are mainly associated with metaphase chromosomes during the G2/M phase [154].
Additionally, they have been shown to translocate in response to stimuli such as
irradiation and serum starvation [143;235;236].
In conclusion, we have identified that the ERE-BP present in breast cancer
extracts are complexes containing the DNA repair proteins Ku70 and Ku80. Our
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preliminary data suggested that presence of these proteins observed by EMSA was
associated with decreased survival in breast cancer patients (Fig 7, Chapter I). Given that
these proteins are involved in the prevention of cell death by apoptosis and are associated
with tumorigenesis and cancer progression, it would be expected that increased DNAbinding activity would be associated with decreased survival. The focus of the
investigations Chapter IV will be to confirm our preliminary results in a larger population
of breast cancer patients.
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CHAPTER IV
CLINICAL UTILITY OF THE DNA-BINDING PROTEIN KU AS A
BIOMARKER OF BREAST CARCINOMA BEHAVIOR

Introduction
The studies reported in Chapter III illustrated that the identity of the ERE-binding
proteins that we observed previously in breast cancer biopsies is the protein Ku. Our
preliminary data suggested that breast cancer patients with tissue biopsies negative for Ku
DNA-binding activity have higher overall survival probabilities than patients positive for
Ku DNA-binding activity. Ku has been implicated in DNA repair, telomere maintenance
and apoptosis and plays an important role in chromosomal integrity and cell survival
[146]. A correlation has been shown between Ku and the development of several cancers.
Over-expression of Ku apparently leads to tumorigenesis through hyperproliferation and
resistance to apoptosis, while under-expression of Ku may lead to genomic instability
[146;237].
Ku protein and mRNA levels have been associated with patient survival and
proliferation in various cancers. For example, Saviozzi et al. measured XRCC5 mRNA
levels in both normal lung and non-small cell lung tumors [238]. Their results showed a
significant correlation between over-expression of XRCC5 and shorter patient survival
probabilities as well as a correlation with increased tumor grade. XRCC5 expression was
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higher in poorly differentiated tumors and over-expression correlated with more
aggressive cancers. Ghezzi et al. also demonstrates that Ku70 gene expression correlated
with poorly differentiated colorectal tumors [239]. In addition, Hu et al. reported that
expression of Ku70 protein measured by IHC was significantly higher in gastric cancers
compared to normal gastric mucosa and precancerous lesions and that over-expression of
Ku70 was associated with shortened telomeres [240].
Parella et al. demonstrated that non-melanoma skin cancers exhibited a significant
increase in both Ku70 and Ku80 protein levels measured by IHC compared to those in
normal skin [241]. This study also measured the DNA-binding activities of Ku in basal
cell carcinomas, squamous cell carcinomas and normal skin tissue. An increase in DNAbinding activity was observed in both the basal and squamous cell carcinomas compared
to the normal skin. Furthermore, over-expression of both proteins was also associated
with an increased rate of tumor cell proliferation. Expression of Ku70 has also been
associated with survival in cervical carcinoma. For example, Wilson et al. reported that
patients whose tumors had low Ku70 protein expression as measured by IHC exhibited
significantly higher survival times [242]. This correlation with overall survival was also
seen for Ku80 although it did not reach statistical significance.
Both Ku70 and Ku80 have been associated with breast cancer progression. Pucci
et al. reported that DNA-binding activities of cytoplasmic Ku measured by EMSA were
increased 2 to 10-fold in tumors compared to normal tissue [243]. They also examined
Ku protein levels by Western blot and found a 4-18-fold increase in expression in tumor
extracts compared to normal tissue extracts. Lagadec et al. using breast cancer cells in
culture, showed that Ku80 associated with the TrkA tyrosine kinase receptor [244].
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Breast tumors expressed higher levels of TrkA compared to normal breast tissue, which
increased cell growth and invasion [245]. Although this study did not evaluate the clinical
significance of Ku80 itself, it was found that Ku80 was upregulated in TrkA overexpressing cells and involved in cell invasion, indicating that Ku80 may have an
important role in breast cancer metastasis. They also showed that Ku70 associated with
TrkA and enhances survival of cancer cells over-expressing this protein [246].
The purpose of the investigations described in this Chapter was to examine the
prognostic significance of Ku DNA-binding activity with regard to breast cancer
recurrence and patient survival. Better understanding of the relationship between Ku
DNA-binding activity in breast cancer biopsies and breast cancer survival will aid in
defining the role of Ku as a potential prognostic biomarker.

Methods and Materials
Patient population

This study utilized de-identified breast carcinoma specimens from 363 patients collected
between 1989-1997 and selected from the IRB-approved Hormone Receptor Laboratory
(HRL) Biorepository and Tumor Marker Database. De-identified human tissue specimens
were collected from patients with primary carcinomas of the breast. Tissue specimens
were typically processed within an hour following surgery using stringent protocols to
ensure the integrity of specimens for genomic and proteomic analyses [20; 191].
Available clinicopathological data include tumor-based properties (e.g., pathology, grade,
stage, size and tumor marker status), patient-related characteristics (e.g., age, race,
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menopausal status, family history, nodal status) and clinical follow-up (e.g, treatment
regimen, disease-free and overall survival).
As a clinical laboratory, the HRL performed biochemical assays measuring the
protein levels of ER and PR in cytosols for

~22,000

human tissue specimens with both

ligand binding and ErA methods for quantification [20]. Breast cancer cytosols
previously prepared and stored at -80°C were used for these investigations. A diagram
describing the flow of breast cancer specimens and associated patients through the study
according to the reporting recommendations for tumor marker prognostic studies
(REMARK) is shown in Figure 34 [247]. Table 4 describes the characteristics of the
patient population used in this investigation. The median patient age was 63 years with a
range of21 to 89.5 years. The median observation time was 70 months and ranged from 1
to142 months. No evidence of bias was detected in the population of patients and
associated breast cancer specimens selected for this study.

Cytosol preparation

Cytosols were prepared from de-identified human breast cancer tissue specimens in 40
mM Tris-HCI, pH 7.4, containing 1.5 mM EDTA, 10% glycerol, 10 mM Na2Mo04, 1
mM PMSF and 10

~M

monothioglycerol, and homogenized with a Polytron PT-I0-35.

Homogenate was separated into pellet and cytosol by centrifugation, using a Beckman
LE-80K ultracentrifuge at 105,000 x g for 30 minutes at 4°C [20;38;39;174]. Protein
concentration of each cytosol was determined by the Bradford procedure [190]. Cytosols
were stored at -80°C for future use.
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De-identified frozen breast cancer
tissue biopsies previously used in
clinical assays of ER & PR

Requirements: Primary breast carcinoma, female
patient, age >18, frozen cytosol in Biorepository,
clinical records in Database

~

Population: Protein extracts from 363
breast tissue specimens

Entire population divided by nodal
status and ERIPR status

Sub-population 2: 43 patients
treated with surgery and adjuvant
chemotherapy

Sub-population 1: 145 patients
treated with surgery alone

Figure 34. REMARK diagram describing the patient population used to investigate the
clinical relevance of Ku. The flow of patients and associated breast cancer specimens
through the study is shown according to the reporting recommendations for tumor marker
prognostic studies (REMARK).
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Table 4. Characteristics of the overall patient population with associated clinical data.
Patient Parameters
Median Age (range)
63 years (21-89.5)
Median Observation time (range)
70 months (1-142)
Race
white
black
asian
hispanic
Histology
Invasive ductal carcinoma
Invasive lobular carcinoma
Other
Median Tumor Size (Range)
60 mm (1-120)
Stage

n
363

292
52

2
1
136
30
45
324

o

9

1

92
178
43
17

2
3
4
Grade
1
2

35
114
113

3
Lymph Node Status
negative
positive
Hormone Receptor Status
ER+/PR+
ER+/PRER-/PR+
ER-/PRRecurrence Status
yes
no
never disease free

99

171
137
200
39
36
88
75
235
53

Determination of DNA-binding activities

Protein extracts were incubated with 50 ng non-specific DNA, poly (dI-dC) (Amersham),

eP]labeled VitA2-ERE sequences in 40 mM Tris-HCI
2

10 mM KCI, 1% glycerol and
buffer, pH 8.0, containing 500

~M

PMSF and 10

~M

monothioglycerol overnight at 4°C.

The gel was pre-run for 30 minutes at 150 V at 4°C in 0.5X TBE buffer (1.0 M Tris-HCI,
pH 8.6, containing 831 mM boric acid, 10 mM EDTA). Samples were then loaded,
followed by electrophoresis at 300 V for 5 minutes, and then 180 V for 4 hours.
Subsequently, gels were dried and exposed to phosphor screens (Perkin Elmer) overnight.
The bands representing

eP]ERE-protein complexes and free ep]ERE sequences were
2

2

visualized and quantified using a Cyclone Storage Phosphor System™ with OptiQuant@
software (Perkin Elmer). A method of estimating the relative DNA-binding activity levels
of ERE-BP in breast cancer biopsies was developed by measuring the band intensity of
the KU/ERE complexes or free

ep]ERE sequences in each lane from the EMSA in
2

OptiQuant@ software (See Chapter II). The Ku DNA-binding activity is reported as
Digital Light Units

(DLU)/~g

protein and normalized to the total DLU of the lane in

order to compare between samples.

Statisical analyses

Graphical analyses, e.g. scatter plots, box and whisker plots, Kaplan-Meier analyses and
linear regression were employed to evaluate various realtionships. For Kaplan-Meier
survival curves, p values were determined with a log-rank test. Chi-square analyses and
statistical analyses (e.g. Kruskal-Wallis, Mann-Whitney tests) were performed with Prism
4 (GraphPad, Inc.). Cox regression analyses were performed using SPSS Statistics 18.0
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(SPSS, Inc.). Kaplan-Meier and Cox regression analyses were performed using relative
Ku70/80 DNA-binding activity levels as determined by EMSA. Kaplan-Meier analyses

were also performed using Ku70 and Ku80 protein levels measured by Western blot and
gene expression levels measured by microarray.

Results and Discussion

Reproducibility of EMSA measurement of Ku DNA -binding activities
To assess the intra-assay variation, Ku DNA-binding activities in cytosols from
ten representative breast carcinomas were measured in three experiments by EMSA using
band intensities from two lanes on the same gel and averaged (Figure 35A). For the
estimate of inter-assay variation, Ku DNA-binding activities of the same ten breast
cancer specimens were measured by EMSA in three separate experiments (Figure 35B).
Results are expressed as mean ± SEM. In general, the reproducibility of the method
developed was satisfactory for performing investigations of the clinical utility of Ku in
assessing breast cancer prognosis.

Relationships of cytosolic Ku DNA-binding activities in breast cancers and various
patient characteristics
Ku DNA-binding activities were measured in cytosols as described using 363
breast cancer biopsies and correlated with various clinical characteristics, including stage,
grade, nodal status, age and race (Figure 36). Box and whisker plots of the data are

101

Inter-Assay

Intra-Assay
A

B

>.-

:;
.: 0.3
._ CI)

~- o.
.S;.:

tl '0 0.2
«5,
g' til 0.2

tl '0 0.2
« 5,
g' til 0.20

._

._ ::t

._ ::t

-g :c

._ c::

CI)

-g :c

0.1

._ c::

0.1

'9 g 0.1

'9 g 0.1

is ~ 0.0

is ~ 0.0

«.c

«.c

o.

2

3

4

5 6 7
Specimen

8

9

10

2

3

4

5 6 7
Specimen

8

9

10

Figure 35. Reproducibility of EMSA measurement of Ku DNA-binding activities. To
assess the intra-assay variation (A), Ku DNA-binding activities in cytosols from ten
representative breast carcinomas were measured by EMSA using band intensities from
two lanes on the same gel and averaged. For the estimate of inter-assay variation (B), Ku
DNA-binding activities of the same ten breast cancer specimens were measured by
EMSA in three separate experiments. Results are expressed as mean ± SEM.
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Figure 36. Inter-relationships of cytosolic Ku DNA-binding activities in breast cancers
and various patient characteristics. Cytosolic Ku DNA-binding activities measured by
EMSA were correlated with stage (A), grade (B), nodal status (C), age CD) and race CE).
Box and whisker plots of the data are shown. The boxes represent the lower quartile,
median and upper quartile, while the whiskers indicate the sample maximum and
minimum. For stage, grade and age, a Kruskal-Wallis test was used to determine if a
significant difference existed between the groups. For nodal status and race, a MannWhitney test was used.
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shown. The boxes represent the first quartile, median (line within the box) and third
quartile, while the whiskers indicate the sample maximum and minimum. For stage,
grade and age, a Kruskal-Wallis test was used to determine if a significant difference
exists between the groups. A Mann-Whitney test was used to examine statistical
significance for nodal status and race.
No significant correlation was observed between Ku DNA-binding activities and
either patient age, race, nodal status, or stage. However a significant correlation was
observed with cancer grade. Patients with higher grade cancers appear to exhibit higher
Ku DNA-binding activities. These observations are consistent with the lung cancer study
by Saviozzi et al. and the Ghezzi et al. colorectal cancer study that correlated higher Ku
levels with poorly differentiated tumors [238;239].
To further examine the relationship of cytsolic Ku DNA-binding activities with
patient characteristics, the population was divided into two groups: those with primary
breast cancers exhibiting below median Ku activity levels and those with above median
Ku activity levels. Chi-square analysis was performed for each parameter to determine if
there was a difference between the two patient groups (Table 5). Results showed that the
increased Ku DNA-binding activity was correlated with node positive cancer (p=O.029)
as well as development of metastases (p=O.008). These results are also consistent with the
Saviozzi et al. lung cancer study that found an association with Ku70 over-expression
and more aggressive tumors [238].
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Table 5. Association of cytsolic Ku DNA-binding activities with vanous patient
characteristics. The population was divided into two groups: those with primary breast
cancers exhibiting below median Ku activity levels and those with above median Ku
activity levels. Chi-square analysis was performed to determine if a difference existed
between the two patient groups.
Below Median
(n=182) No. (%)

Above Median
(n=181) No. (%)

<35
35-50
>50

4 (2)
48 (26)
130 (71)

4 (2)
46 (25)
131 (72)

S20mm
>20mm
missing

83 (46)
81 (44)
18 (10)

63 (35)
96 (53)
22 (12)

Positive
Negative
missing

62J34)
100 (55)
20 (11)

75 (41)
72 (40)
34 (19)

I
II
III
missing

24(13)
53 (29)
54 (30)
51 (28)

11 (6)
61 (34)
59 (16)
50 (28)

0
I
II
III
IV
missing

4 (2)
55 (30)
84 (46)
20 (11)
7 (4)
12 (7)

5 (3)
36 (20)
94 (52)
23 (13)
10 (5)
13 (7)

Infiltrating Ductal
Invasive Lobular
Other
missing
Hormone Receptor Status
ER+/PR+
ER+/PRER-/PR+
ER-/PRTreatments
Surgery Only
Chemotherapy
Hormonal therapy
Radiation therapy
Combined therapies
Development of metastasis
Yes
No
Never disease free

136 (75)
14 (8)
29.116)
3 (2)

135 (75)
16 (9)
26 (14)
4 (2)

100 (55)
21 (12)
22 (12)
39 (21)

100 (55)
18(10)
14 (8)
49 (27)

75141}
28(15)
30 (16)
8 (4)
41 (23)

70 (39)
37 (20)
21 (12)
12 (7)
41 (23)

29 (16)
132(36)
22 (6)

46 (25)
103 (28)
31 (8)

Age

Pvalue
0.978

0.057

Tumor Size

0.029

Nodal Status

0.061

Grade

Stage

0.252

Histology

0.875

0.37

0.433

0.008
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Significance of known prognostic indicators
To ensure that the population of patients used in this study is representative of the
general population of breast cancer patients, survival analysis was performed with known
prognostic factors. Kaplan-Meier analyses were used to determine the relationship
between survival and stage, nodal status and grade in the study population (Figure 37).
As anticipated, higher stage, higher grade and positive nodal status were associated with
decreased disease-free (DFS) and overall (OS) survival probabilities [3;12]. KaplanMeier analyses were also used to determine the relationship between survival and ERiPR
status of the breast carcinoma in the study population (Figure 38). Patients with either ER
or PR negative breast carcinomas were associated decreased disease-free and overall
survival probabilities compared to those patients with ER or PR positive cancers. As
described previously, breast cancer patients with tumors that are ER and/or PR positive
generally exhibit increased disease-free and overall survival [3]. These results suggest
that this population is representative of the general population of patients with primary
breast cancers.

Correlation of cytosolic Ku DNA-binding activities with survival of breast cancer
patients
Our preliminary data described in Chapter I suggested that presence of Ku (then
called ERE-BP) in breast cancer cytosols correlated with patient survival. To further
evaluate this finding, Ku DNA-binding activities were measured by EMSA using
cytosols prepared and analyzed as described previously. Kaplan-Meier analyses were
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Figure 37. Disease-free and overall survival probabilities of the study population as a
function of known prognostic indicators. Kaplan-Meier analyses were used to determine
the influence of stage (A & B), nodal status (C & D) and grade (E & F) on disease-free
(DFS) and overall (OS) survival. P values were determined using a log-rank test.

107

B

A
-1

-1

C

!L.

n=239

Ii
>

~

~

CI)

Ii
>

n=124

60

~

CI)

~
III
'5

40

E

P=O.064

~

~

75
100 125
25
50
DFS (Months to Recurrence)

150

0

C

....£... pR Postille
....£... PR Negatille

~

!L.

Ii
>

80

~

60

n=236

Ii
>

.~

~

~

CI)

a>

n=127

a>

>

40

~

III

40

III

'5

'5

E 20

E 20

~

0

150

-100

C

>

25
50
75
100
125
OS (Months After Surgery)

0

-100

~

P=O.012

0

0
0

CI)

n= 124

a>

E 20

0

n=239

~

a>

~
III
'5

....£... ER Positille
....£... ER Negatille

~

~

P=O.032

0
0

25
50
75
100 125
DFS (Months to Recurrence)

0

150

P<O.OOO1
0
0

25
50
75
100 125
OS (Months After Surgery)

150

Figure 38. Disease-free and overall survival probabilities of the study population as a
function of ER and PR status of the breast carcinomas. Kaplan-Meier analyses were used
to detenrune the influence of ER status (A & B) and PR status (C & D) on disease-free
(DFS) and overall (OS) survival. Using established criteria, a level greater than 10
fmoVrng protein by ligand binding and 15 fmoVrng protein by enzyme immunoassay
were used to distinguish between ERIPR positive and negative samples [35]. P values
were determined using a log-rank test.

108

A
~

e.....

B
~100

100

e.....

iij

.>...>
:J

(/)

iij

>

60

:J

Above tledian Ku (n=181)

(/)

Q)

>
;:

80

.~

60
Above tledian Ku (n=181)

Q)

>

40

;:
cu

cu

"3

40

"3

E 20

E 20

p= 0.022

:J

0

0

75
100
125
25
50
DFS (Months to Recurrence)

:J

p=0.030

0

150

0

50
~
100
1~
OS (Months after Surgery)

~

150

Figure 39. Disease-free and overall survival probabilities as a function of Ku DNAbinding activity in breast carcinomas. Ku DNA-binding activities were measured by
EMSA using cytosols prepared and analyzed as described previously. Kaplan-Meier
analyses were used to determine the relationship of Ku DNA-binding activities with
disease-free (DFS) (A) and overall (OS) (B). The patient population was divided into two
groups with either Ku DNA-binding activities above or below the median value,
regardless of ERiPR status. P values were determined using a log-rank test.

109

used to detennine the relationship of Ku DNA-binding activities with DFS and OS
(Figure 39). The patient population was divided into two groups with either Ku DNAbinding activities above or below the median value. Patients with increased Ku DNAbinding activities had decreased disease-free (p=0.022) and overall survival (p=0.030)
probabilities. DFS percentages for patients with tumors with increased Ku binding
activities were 67% compared to 79% for patients with decreased activities (p=0.022).
For OS percentages, patients with tumors with increased Ku binding activities were 62%
compared to 74% for patients with decreased Ku binding activities (p=0.030).
To analyze the relationship between survival and Ku DNA-binding activity as a
continuous variable, univariate Cox regression analysis was perfonned for both DFS and
OS (Table 6). The hazard ratio for DFS was 4.88 (p=0.002) while the hazard ratio for OS
was 2.14 (p=0.192). The hazard ratio is a means of relating the Ku DNA-binding activity
value to survival. A hazard ratio of 1 indicates that Ku DNA-binding activity has no
effect on survival, while a value of <1 indicates that higher Ku DNA-binding activity is
correlated with increased survival. A hazard ratio of> 1 indicates that higher Ku DNAbinding activity is correlated with decreased survival. Thus the hazard ratios of 4.88 and
2.14 indicate that higher Ku DNA-binding activities in tissue biopsies are associated with
decreased survival in breast cancer patients.
In Chapter III, we documented a correlation between Ku DNA-binding activities
and protein levels measured by Western blot. To detennine if Ku70 and Ku80 protein
levels also correlated with survival, Kaplan-Meier analyses were used to detennine the
relationship of Ku protein levels with DFS and OS (Figure 40). Ku70 and Ku80 were
measured by Western blot as described previously in a population of 50 patients. The
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Table 6. Influence of Ku DNA-binding activity in frozen breast cytosols from breast
carcinomas for predicting the disease-free and overall survival of patients. Univariate
Cox regression analyses were performed as a function of Ku DNA-binding activities
determined by EMSA as described previously.

Hazard Ratio (95% CI)

P value

DFS

4.88 (1.78-13.36)

0.002

OS

2.14 (0.681- 6.75)

0.192
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Figure 40. Disease-free and overall survival probabilities as a function of Ku70 and Ku80
protein levels. Ku70 and Ku80 protein levels were measured in previously frozen breast
cancer cytosols by Western blot as described in Chapter III. Kaplan-Meier analyses were
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DFS and OS. The patient population was divided into two groups with either Ku DNAbinding activities above or below the median value in breast tissue biopsies. These
patients had breast cancers that were both ER negative and positive. P values were
determined using a log-rank test.
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patient population was divided into two groups according to Ku protein levels either
above or below the median value in breast cancers. P values were determined using a logrank test. The same trend of higher Ku levels associating with lower survival probabilities
was observed for DFS, although it was not statistically significant. However, there was
no correlation with OS. This is most likely due to the small population size and an
expanded study is warranted in a larger group of breast cancer specimens.
Disease-free and overall survival probabilities as a function of XRCC5 (Ku80) or
XRCC6 (Ku70) gene expression levels were also analyzed (Figure 41). Kaplan-Meier
analyses were performed using gene expression data from micro array analysis of LCMprocured carcinoma cells from 247 biopsies [200;248] to determine the influence on DFS
and OS. The patient population was divided into two groups with breast carcinomas
exhibiting either Ku gene expression levels above or below the median value. No
significant correlation with survival was observed for either DFS or OS.
These data are inconsistent with the earlier clinical correlations with the DNAbinding activities as well as the studies by Saviozzi et al. and Ghezzi et al. Both of these
studies measured gene expression levels by qRT-PCR instead of microarray. Because of
the broad nature of microarray analysis, qRT-PCR is a more accurate method of
validating gene expression data [249]. Microarray results are usually validated by qRTPCR.
Another possible explanation for the difference observed is tissue specific
variability in expression. Our study focuses on breast tumors while the Saviozzi and
Ghezzi studies focused on lung and colorectal tumors. Furthermore, post-translational
modifications may playa role in the ability of Ku binding to DNA, since Ku has been
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reported to be both acetylated and phopshorylated [246;250;251]. Ku70 and Ku80 are
targets of phosphorylation by DNA-PK and this phosphorylation apparently controls their
localization, DNA-binding and function [251]. The C-terminal region of Ku70 is
acetylated by CBP and PCAF, disrupting the Ku70-Bax interaction [250].

Correlation of Ku DNA -binding activities with survival in various sub-populations of
patients
Since ER and PR expression in a primary breast cancer biopsy serve as indicators
of a patient's prognosis, we combined ERiPR status with either above or below median
Ku DNA-binding activity to determine the relationship with DFS and OS (Figure 42).
Survival results of patients with ER-/PR- breast carcinomas accepted as those with the
poorest prognosis are shown in A and B. Survival results for patients with tumors that are
either ER-/PR+ or ER+/PR- breast carcinomas are shown in C and D, while those from
patients with the best prognosis exhibiting breast cancers that are ER+/PR+ are shown in
E and F. The median Ku DNA-binding activity of the entire population of 363 patients
was used as a cutoff. A level greater than 10 fmol/mg protein by ligand binding and 15
fmol/mg protein by enzyme immunoassay were used to distinguish between either ER or
PR positive and negative samples [35]. P values were determined using a log-rank test.
A significant difference in DFS and OS was not observed between the patients
with either increased or decreased Ku activities that also had ER+/PR+ breast
carcmomas. However, breast cancer patients with tumors that are either ER-/PR-,
ER+/PR- or ER-/PR+ and exhibit above median Ku DNA-binding activities exhibited the
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Figure 42. Disease-free and overall survival probabilities as a function of both Ku DNAbinding activity and ERiPR status of breast carcinomas. Ku DNA-binding activities were
evaluated according to ERIPR status and Kaplan-Meier analyses were used to determine
the relationship with DFS and OS. Survival results of patients with ER-IPR- breast
carcinomas are shown in A and B. Survival results for patients with tumors that are either
ER-IPR+ or ER+IPR- breast carcinomas are shown in C and D, while those that are
ER+IPR+ are shown in E and F. The median Ku DNA-binding activity of carcinomas
from the entire population of 363 patients was used as a cutoff. A level greater than 10
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fmol/mg protein by ligand binding and 15 fmol/mg protein by enzyme immunoassay
were used to distinguish between ER positive and negative samples [35]. P values were
determined using a log-rank test.
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as and DFS. Breast carcinomas that do not express ER or PR as well as those

poorest

expressing only one of these receptor proteins are generally found to be more aggressive
and less differentiated than ER+/PR+ breast cancers [3]. Since Ku expression is increased
in more aggressive cancers, it would be expected that Ku DNA-binding activity exhibits a
stronger association with decreased survival in breast cancers that are ER and/or PR
negative. These patients are also much less likely to respond to drugs such as tamoxifen
[25;26].

Since nodal status is a major prognostic factor in breast cancer, we assessed the
relationship between Ku DNA-binding activities in tissue biopsies with patient survival
as a function of nodal status (Figure 43). Ku DNA-binding activities were combined with
nodal status and Kaplan-Meier analysis was used to determine the relationship with DFS
and OS. Survival results of patients with node negative breast carcinomas are shown in A
and B, while those for node positive breast carcinomas are shown in C and D. The
median Ku DNA-binding activity of the entire population of 363 patients was used as a
cutoff. P values were determined using a log-rank test. Increased Ku DNA-binding
activity was associated with decreased DFS in node positive patients (p=O.046), however
the relationship was not statistically significant in node negative patients. This also
supports our observation that Ku DNA-binding activity in a tissue biopsy has increased
relevance for predicting more aggressive cancers and increased risk of recurrence.
To confirm that these results are independent of therapy received, a subset of
patients that received surgery alone without adjuvant therapy was analyzed by KaplanMeier (Figure 44). Patients with tumors exhibiting Ku DNA-binding activities in the
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above median group had decreased DFS (p=O.150) and OS (p=O.003) probabilities.
Although the p value for DFS was not significant, the trend of higher Ku DNA-binding
activities being associated with decreased survival probabilities was observed. These
results suggest that the use of Ku-binding activity as a predictor of risk of recurrence is
independent of therapy received by the patient.
Because Ku is involved in DNA repair and certain chemotherapies induce DNA
damage, we wanted to determine the clinical utility of Ku DNA-binding in a subset of
patients receiving only adjuvant chemotherapy. Patients described in this population had
been treated with various combinations of the DNA damaging agents doxorubicin,
cyclophosphamide, methotrexate or 5-fluorouracil. Doxorubicin is an anthracycline that
works by intercalating DNA, while cyclophosphamide is an alkylating agent that attaches
an alkyl group to guanine bases in DNA. Methotrexate is an anti-folate that inhibits
dihydrofolate reductase thereby blocking thymidine synthesis. Furthermore, 5fluorouracil is a pyrimidine analog that inhibits thymidylate synthase. Kaplan-Meier
analyses were used to determine the relationship of Ku DNA-binding activities to
disease-free and overall survival in 43 patients receiving surgery and adjuvant
chemotherapy (Figure 45). All patients were without distant metastases at presentation.
The median value of the Ku DNA-binding activities in cancers from the entire population
of 363 patients was used as a cutoff. P values were determined using a log-rank test.
Increased Ku DNA-binding activities were associated with decreased DFS (p=O.004) and
OS (p=O.009) in a statistically significant manner. After 125 months, 97% of patients
with breast cancers in the below median group had not developed a recurrence compared
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population of 363 patients was used as a cutoff. P values were determined using a logrank test.
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to only 55% in the above median group. A Fisher's exact test was used to determine
whether a difference exists between these two groups in relation to grade and nodal
status; however no significant differences were found (Table 7). The Fisher's exact test
was used instead of chi-square analyses due to the small population size. Additionally, no
significant difference was found in average tumor size between groups. These data
underscore the importance of this research since we have shown that Ku DNA-binding
activity in a breast tumor biopsy may predict response to chemotherapy independent of
nodal status, tumor grade or tumor size.
Our results show that increased Ku DNA-binding activities in breast cancer
tumors are associated with lower survival probabilities under a variety of clinical and
tumor marker states. Several studies discussed earlier found that over-expression of Ku70
and Ku80 is associated with tumor progression in breast, lung, colorectal, skin, gastric
and cervical carcinomas [238-243]. Ku levels in the majority of these studies were
measured either by IHC or qRT-PCR. Additionally, only two studies measured the DNAbinding activities ofKu in tumor extracts [241;243]. Both studies showed that Ku DNAbinding activities were increased in cancer tissue extracts compared to normal tissue
extracts. Pucci et at., using breast cancer cytosolic extracts, reported Ku DNA-binding
activities were increased 2 to 10-fold in tumors compared to those from normal tissue
[243]. However, a limitation of this study was the small population size (n=8).
Parella et at. showed that an increase in DNA-binding activity was observed in
both basal and squamous cell skin carcinomas compared to normal skin. The overexpression of both Ku proteins was also associated with an increased tumor proliferation
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Table 7. Comparison of clinical parameters between the two prognostic groups in a
subset of patients receiving adjuvant chemotherapy only. Grade and nodal status were
analyzed by a Fisher's exact test. For tumor size, mean ± SEM was compared by a MannWhitney test.

Grade 1 and 2
Grade 3 and 4
Node Negative
Node Positive
Tumor Size (mm)

Ku Below Median (n=24)
4
15
12
12
26± 2
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Ku Above Median (n=19)
6
10
7
11
29± 4

p
0.45
0.54
0.98

rate. Although our investigation did not examine Ku DNA-binding activities in normal
breast specimens, our data also suggest that higher Ku activity is associated with tumor
progression and metastasis. We observed a significant correlation with higher tumor
grade and lymph node positive cancers, both indicators of more aggressive breast
cancers.
Two of the studies discussed earlier correlated Ku expression levels with patient
survival. Wilson et at. measured Ku70 and Ku80 protein levels by IHC in 77 cervical
carcinoma biopsies [242]. Kaplan-Meier survival analysis showed that high Ku70 and
Ku80 levels were associated with lower overall survival probabilities in patients
receiving radiotherapy. The percent survival at 60 months for patients with tumors
exhibiting high Ku70 expression compared to those with low expression was 47% and
69%, respectively (p=0.046). The percent survival at 60 months for patients with tumors
exhibiting high Ku80 expression compared to those with low expression was 50% and
69%, respectively (p=0.087). Saviozzi et al. correlated Ku80 gene expression levels in
non-small cell lung cancer biopsies with overall survival of 50 patients [238]. KaplanMeier survival analysis showed that high Ku80 levels in lung lesions were associated
with lower overall survival probabilities. The percent survival at 60 months for patients
with lung tumors with high Ku80 expression compared to those with low expression was
15% and 68%, respectively (p=0.04). Cox regression analysis also showed that Ku80
over-expression was associated with poor prognosis (hazard ratio = 0.005).
The results of both these studies with different types of carcinoma are similar to
our results with breast cancer which showed that DFS percentages for patients with
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tumors with high Ku binding activities compared to those with low activities were 67%
and 79%, respectively (p=0.022). Patients with tumors with high Ku binding activities
compared to low exhibited OS values of 62% and 74%, respectively (p=0.030). This
work extends beyond protein expression and correlates DNA-binding activity with
prognosis. Furthermore, our investigation has utilized a much larger patient population
than the studies previously mentioned.
Our results also suggested that Ku DNA-binding activity in a breast tumor biopsy
may predict response to chemotherapy. Over-expression of DNA repair proteins in a
tumor cell potentially may promote resistance to DNA damage induced by chemotherapy
and radiation leading to a less effective therapeutic outcome. Several studies have
reported that Ku70 and Ku 80 expression is related to resistance to radiotherapy. As
discussed above, Wilson et al. measured Ku70 and Ku80 protein levels by IHC in 77
cervical carcinoma biopsies [242]. Kaplan-Meier survival analysis indicated that high
Ku70 and Ku80 levels were associated with lower overall survival probabilities in
patients receiving radiotherapy.
Beskow et al. also reported that cervical cancer patients resistant to radiotherapy
over-express Ku70 and Ku80, as determined by IHC [252]. In addition, Komuro et al.
reported similar results in patients with rectal carcinoma [253]. Ku70 and Ku80 protein
levels measured by IHC significantly correlated with radiotherapy resistance while overexpression of both proteins associated with shorter disease-free survival times in patients
receiving radiotherapy. Lee et al. reported that high Ku70 protein expression in
nasopharyngeal carcinoma also correlated with resistance to therapy [254]. They
suggested that Ku70 expression predicts response to radiotherapy as well as response to
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radiotherapy with concurrent chemotherapy in patients with this aggressive cancer. In
breast cancer, Leifler et al. reported that low protein expression of Ku70 and Ku80
predicted a good response to radiotherapy [255]. These results suggest that tumors with
high levels of Ku70 and Ku80 are able to repair damaged DNA after radio- or
chemotherapy allowing them to survive and proliferate.
As documented in the preceding discussion, there is emerging evidence from
studies of various types of cancer that the XRCC5 and XRCC6 genes and their protein
products, Ku80 and Ku70 are correlated with a broad spectrum of clinical features and
disease parameters in patients. Thus far, no common relationship has been discerned
between Ku70/Ku80 expression and a particular clinical behavior. To our knowledge, our
results using a short, defined DNA sequence represent the first correlation between Ku
DNA-binding activity and response to chemotherapy in breast cancer.
Resistance to cytotoxic therapy is likely only part of the reason that patients with
tumors either over-expressing Ku70 and Ku80 protein levels or showing increased DNAbinding activities have shorter survival times than patients with tumors expressing lower
Ku levels. Our results also indicated that this trend is true in patients receiving only
surgical resection of the primary tumor, suggesting additional mechanisms for this
difference in survival. Since NHEJ is error-prone and has been reported to cause
chromosomal rearrangements, an over-expression of Ku may lead to increased
chromosomal instability and tumor progression [256;257]. This is especially important in
breast tissue because of the extensive differentiation, proliferation and apoptosis that
occurs during development in utero, puberty, monthly pre-menopausal cycles and
pregnancy [100-102]. These high proliferation rates enhance the likelihood of DNA

127

breaks [241]. To complicate the possible mechanism further, Ku is also involved in
telomere maintenance and apoptosis. Ku70 has been reported to be associated with
telomere shortening in gastric cancer, leading to genetic instability and carcinogenesis
[240]. Ku70 expression also appears to be related to suppression of apoptosis, an
important mechanism in tumor suppression [258]. Over-expression of Ku70 sequesters
the pro-apoptotic protein Bax from the mitochondria rendering it inactive [144;250].
These mechanistic studies provide supportive evidence for the molecular basis of the
clinical correlations observed from our investigations of breast carcinoma.

Summary & Conclusions

The purpose of the investigations reported in this Chapter was to examine the
clinical value of determining Ku DNA-binding activity in breast cancer tissue biopsies
such as assessing risk of recurrence and overall survival as well as response to therapies.
Better understanding of the relationship between Ku DNA-binding activity in breast
cancer biopsies and breast cancer behavior will help define Ku as a potential prognostic
biomarker.
Our results demonstrated that increased Ku DNA-binding activities measured in
cytosols of breast tumor biopsies correlated with higher grade tumors, positive lymph
node status and disease-free and overall survival. These results were also detected in a
subset of patients that didn't receive adjuvant therapy. Most importantly, these results
were also observed in patients receiving adjuvant chemotherapy, suggesting that Ku
DNA-binding activities may be used to predict response to treatment with toxic agents.
Cox regression analysis indicated that higher Ku DNA-binding activities were associated
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with an increased risk of breast cancer recurrence and decreased survival. Collectively,
our results suggest that Ku DNA-binding activities in cytosols prepared from breast
cancer biopsies may be used as potential biomarkers to improve breast cancer
management.
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APPENDIX
Table 8. List of DNA sequences.
Name
Bel2
CTSD
GRE
c-fos
Jun
OCTI
OCT2
PR-b
PRE
Prolactin
pS2
Scramble-l
Scramble-2
TFIID
TREpal
TRE-DR
VitA2
VitA2-HP

VitA2-mut

Sequence
S'-GTCCGGTCGCCAGGACCT-3'
S'-GTCGATCAGCTGGGCCGGGCTGACCCCGCG-3'
S'-GTCAGAGGATCTGTACAGGATGTTCTAGAT-3'
S'-AGCTTGGGCTGAGCCGGCAGCGTGACCCCGCATG-3'
S'- GTCGATCCTGAAGCAGAGCATGACCTTGAACTGAAG
CAGAGCAT GACCTTGAA-3'
S'-GTCATTTGCAT -3'
S'-GTCGGCGTTAAAATTCATTAAAATTCAGGCC-3'
S'-GTCATGGAGGCCAAGGGCAGGAGCTGACCAGCGCCG
CCCT-3'
S'-GTCGATCCAGAACAAACTGTTCTAGCTACG-3'
S'-GTCTCCAGGTCACCAGCTGCTTCAGATGATC-3'
S'-GTCGATCTGCAAGGTCACGGTGGCCACCCC-3'
S'-GTCAGGTTTGAGGCTATATAGTGAAAGA-3'
S'-GTCTGGTCATACGAGTAAGCTGAGGATGAGCGCCG
AAC-3'
S'-GTCGCAGAGCATATAAGGTGAGGTAGGA-3'
S'-GTCGATCGTAAGATTCAGGTCATGACCTGA-3'
S'-GTCAGCTTCAGGTCACAGGAGGTCAGAGAG-3'
S'-GTCCAAAGTCAGGTCACAGTGACCTGATC-3'
S'-TTTGCGGTCCAAAGTCAGGTCACAGTGACCTGATCGT
TTTTTTTCGATCAGGTCACTGTGACCTGACTTTGGACCG
C-3'
S'-CAAAGTCAGGGCACAGTGTCCTGATC-3'

IS3

Ref.
[2S9]
[260]
[261]
[262]
[263]
[264]
[264]
[26S]
[263]
[266]
[267]

[187]
[268]
[269]
[173]

Table 9. List of abbreviations.
aa
AJCC
BIR
CI
DC IS
DFS
dHJ
DLU
DLU
DNA-PK
DSB
DTT
E2
EIA
EMSA
ER
ERE
ERE-BP

ERR
ETOH
FDA
FISH
GRE
HAP
hnRNP
HRE
HRL
HRP
IHC
IRB
Kd
LBA
LCIS
LCM
LC-MS/MS
NE
NHEJ
NLS
OS
PAGE
PMSF
PR
REMARK
rhER

amino acid
American Joint Committee on Cancer
break induced replication
confidence interval
ductal carcinoma in situ
disease free survival
double Holliday junction
digital light units
digital light units
dna protein kinase
double strand break
dithiothreitol
17p-estradiol
enzyme Immunoassay
electrphoretic mobility shift assay
estrogen receptor
estrogen response element
estrogen response element binding proteins
estrogen related receptor
ethanol
Food and Drug Administration
fluorescent in situ hybridization
glucocorticoid response element
high abundant proteins
heterogeneous ribonucleoprotein
hormone response element
hormone receptor laboratory
horseradish peroxidase
immunohistochemistry
institutional review board
dissociation constant
ligand binding assay
lobular carcinoma in situ
laser capture microdissection
tandem liquid chromatography and mass spectrometry
nuclear extract
nonhomologous end joining
nuclear localization signal
overall survival
polyacrylamide gel electrophoresis
phenylmethanesulfonylfluoride
progesterone receptor
reporting recommendations for tumor marker prognostic studies
recombinant human estrogen receptor
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Rlx
RPA
SDSA
SEM
SERM
Tmx
TRE
VitA2
vWa

raloxifene
replication protein A
synthesis dependent strand annealing
standard error of the mean
selective estrogen receptor modulator
tamoxifen
thyroid hormone response element
vitellogenin A2
von Wille brand
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